phenylalanine has been researched along with Diabetes Mellitus, Adult-Onset in 227 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (0.44) | 18.7374 |
| 1990's | 15 (6.61) | 18.2507 |
| 2000's | 141 (62.11) | 29.6817 |
| 2010's | 59 (25.99) | 24.3611 |
| 2020's | 11 (4.85) | 2.80 |
| Authors | Studies |
|---|---|
| Arthur, RM; Banik, SM; Carl, CS; Contrepois, K; He, Y; Jansen, RS; Kiens, B; Kim, JT; Li, VL; Liu, H; Loh, KY; Long, JZ; Lyu, X; Michael, B; Moeller, BC; Richter, EA; Snyder, MP; Stahl, A; Tanzo, JT; Terrell, SM; Tung, AS; van de Wetering, K; Voldstedlund, CT; Wallis, GA; Wei, W; Wiggenhorn, AL; Xu, Y; Yang, AC; Zushin, PH | 1 |
| Kejun, W; Libin, L; Lijing, W; Linxi, W; Liqin, Q; Lishan, H; Mengjun, Z; Sujie, K; Xiaohong, L; Xiaoying, L; Zhidong, Z | 1 |
| An, YP; Chen, JC; Huang, L; Li, YM; Lin, PC; Lin, Y; Liu, J; Sun, WW; Sun, WX; Wu, BX; Xu, W; Yuan, YY; Zhang, HL; Zhao, JY; Zhao, SM; Zhou, Q; Zhou, XW | 1 |
| Alrokayan, SA; Hussain, T; Kutala, VK; Naushad, SM | 1 |
| Huang, C; Lin, D; Lu, R; Zhang, Y; Zhou, L; Zou, H | 1 |
| Jia, Y; Jiang, T; Li, S; Ren, Z; Wang, J; Wang, L; Wang, Z; Yu, Y | 1 |
| Shanmugam, G; Unnikrishnan, AC | 1 |
| Barajas-Galicia, E; Cabrera-Nieto, SA; Camacho-Rea, MDC; Coronado-Zarco, I; Fernández-Lainez, C; Gonzalez-Fernández, NC; Herrera-López, B; Ibarra-González, I; Jimenez-Gutierrez, GE; Juárez-Arias, M; Lopez-Cisneros, G; López-Reyes, A; Magaña, JJ; Martinez-Armenta, C; Martínez-Gómez, LE; Martínez-Nava, GA; Martínez-Ruiz, FJ; Moreno, ML; Moreno-Macías, H; Olea-Torres, J; Ortega-Peña, S; Pineda, C; Posadas-Sanchez, R; Ramírez-Hinojosa, JP; Rodríguez-Zulueta, AP; Rojas-Velasco, G; Rosas-Vásquez, M; Sánchez-Muñoz, F; Suarez-Ahedo, C; Tusie, T; Valdespino-Vázquez, MY; Vargas-Alarcón, G; Vázquez-Cárdenas, P; Vela-Amieva, M; Vidal-Vázquez, P; Zayago-Angeles, DM | 1 |
| Friedenberg, FK; Piech, G; Reichenbach, ZW; Selby, A | 1 |
| Ahola-Olli, AV; Ala-Korpela, M; Auvinen, J; Havulinna, AS; Järvelin, MR; Jokelainen, J; Juonala, M; Kähönen, M; Kalimeri, M; Keinänen-Kiukaanniemi, S; Kettunen, J; Lehtimäki, T; Mustelin, L; Perola, M; Puukka, K; Raitakari, O; Salomaa, V; Würtz, P | 1 |
| Fang, ZZ; Feng, XF; Li, J; Luo, HH; Sun, XY; Yang, X | 1 |
| Barazzoni, R; Kiwanuka, E; Tessari, P; Vedovato, M; Vettore, M; Zanetti, M | 1 |
| Cho, YM; Choe, HJ | 1 |
| Bain, JR; Ilkayeva, OR; Lowe, LP; Lowe, WL; Metzger, BE; Muehlbauer, MJ; Newgard, CB; Nodzenski, M; Reisetter, AC; Scholtens, DM; Stevens, RD | 1 |
| Dupuis, J; Flannick, J; Florez, JC; Gerszten, RE; Leong, A; Levy, D; Liu, CT; Meigs, JB; Merino, J; Porneala, B; von Grotthuss, M; Walford, GA; Wang, TJ | 1 |
| Rendell, MS | 1 |
| Kuusisto, J; Laakso, M; Smith, U; Stancáková, A; Vangipurapu, J | 1 |
| Hu, Y; Liu, T; Liu, Y; Tang, L; Wu, H; Wu, P; Wu, Y | 1 |
| Anderwald, CH; Bernroider, E; Brehm, A; Krebs, M; Krssak, M; Nowotny, P; Phielix, E; Roden, M; Schmid, AI | 1 |
| Harada, K; Miyachi, A; Murase, T; Osonoi, T; Yamada, Y | 1 |
| Bao, Y; Jia, W; Li, H; Mo, Y; Peng, Y; Zhang, X; Zhou, J | 1 |
| Katsiki, N; Kolovou, G | 1 |
| Bethel, MA; Califf, RM; Chang, F; Disertori, M; Giles, TD; Haffner, SM; Holman, RR; Latini, R; Maggioni, AP; McMurray, JJ; Rutten, GE; Standl, E; Staszewsky, L; Sun, JL; Thomas, L; Tognoni, G | 1 |
| Bethel, MA; Califf, RM; Charbonnel, B; Diem, P; Haffner, SM; Holman, R; Horton, ES; Krum, H; Leiter, LA; Mareev, V; McMurray, JJ; Reyes, EM; Schaper, F; Shah, BR; Shen, L; Soska, V; Sun, JL; Thomas, L; Wojdyla, D | 1 |
| Chen, M; Hu, C; Jia, W | 1 |
| Bao, Y; Deng, Z; Jia, W; Li, H; Lu, J; Mo, Y; Peng, Y; Zhang, X; Zhou, J | 1 |
| Nakashima, E | 1 |
| DeFronzo, RA; Ferrannini, E | 1 |
| Fukase, H; Harigai, M; Iida, S; Ikeda, S; Kasahara, N; Miyata, K; Ohba, Y; Saito, T; Takano, Y; Terao, K | 1 |
| Abdulla, H; Atherton, PJ; Idris, I; Smith, K | 1 |
| Bao, Y; Chen, T; Hu, C; Huang, F; Jia, W; Liu, J; Ma, X; Ni, Y; Xie, G; Zhao, A | 1 |
| Burd, NA; Cermak, NM; Churchward-Venne, TA; Gijsen, AP; Kouw, IW; Senden, JM; van Loon, LJ | 1 |
| Beavers, LS; Efanov, AM; Fang, X; Gonzalez Valcarcel, IC; Lin, HV; Ma, T; Wang, J; Wang, X | 1 |
| Bao, Y; Chen, T; Hu, C; Huang, F; Jia, W; Ma, X; Ni, Y; Rajani, C; Zhao, A; Zheng, X | 1 |
| Hemmingsen, B; Metzendorf, MI; Richter, B; Sonne, DP | 1 |
| Harumi Higuchi Dos Santos, M; Holman, RR; Lopes, RD; McMurray, JJ; Pieper, K; Sharma, A; Sun, JL | 1 |
| Bilker, WB; Brensinger, CM; Chiang, C; Han, X; Hennessy, S; Leonard, CE; Li, L | 1 |
| Hick, C; Koole, C; Mobarec, JC; Reynolds, CA; Sakmar, TP; Sexton, PM | 1 |
| Asano, T; Doi, Y; Iida, M; Iino, K; Iwase, M | 1 |
| Cicero, AF; D'Angelo, A; Derosa, G; Ferrari, I; Fogari, E; Gravina, A; Salvadeo, S | 2 |
| Li, C; Wang, L; Wang, S; Xia, J; Zhang, G | 1 |
| Baron, MA; Israel, MK; Istvan, E | 1 |
| Kawashima, Y; Kudo, N; Shiba, S; Tamura, M | 1 |
| Juurinen, L; Kauppinen-Mäkelin, R; Kock, T; Kotronen, A; Lanki, H; Leppävuori, E; Nikkilä, K; Saltevo, J; Teikari-Myyrä, T; Tiikkainen, M; Yki-Järvinen, H | 1 |
| Cornelius, V; Kasliwal, R; Shakir, SA; Vlckova, V; Wilton, L | 1 |
| Gao, X; Gao, Y; Li, GW; Liu, X; Pan, CY; Zhu, XX | 1 |
| Davis, SN | 1 |
| Buse, JB; Einhorn, D | 1 |
| Bell, PM; Duffy, NA; Flatt, PR; Green, BD; Lindsay, JR; McKillop, AM; O'Harte, FP; Patterson, S | 1 |
| Longo, R | 1 |
| Bryant-Mills, R; Copley, RC; Facchine, KL; Johnson, B; Joshi, BK; Leblanc, MP; Osterhout, M; Patterson, DE; Powers, J; Ramsey, B; Sides, SL | 1 |
| Nathan, DM | 1 |
| Belenkov, Y; Bethel, MA; Boolell, M; Buckley, BM; Buse, JB; Califf, RM; Chacra, AR; Charbonnel, B; Chiang, FT; Chow, CC; Davies, MJ; Deedwania, P; Diem, P; Einhorn, D; Fonseca, V; Fulcher, GR; Gaciong, Z; Gaztambide, S; Giles, T; Haffner, SM; Holman, RR; Holzhauer, B; Horton, E; Hua, TA; Ilkova, H; Jenssen, T; Kahn, SE; Krum, H; Laakso, M; Leiter, LA; Levitt, NS; Mareev, V; Martinez, F; Masson, C; Mazzone, T; McMurray, JJ; Meaney, E; Nesto, R; Pan, C; Prager, R; Raptis, SA; Rutten, GE; Sandstroem, H; Schaper, F; Scheen, A; Schmitz, O; Sinay, I; Soska, V; Stender, S; Tamás, G; Tognoni, G; Tuomilehto, J; Villamil, AS; Vozár, J | 2 |
| Inoue, T; Kato, T; Node, K | 1 |
| Scheen, AJ | 1 |
| Grasso, DM; La Rosa, C; Milardi, D; Pappalardo, M; Sciacca, MF | 1 |
| Kang, W; Kim, Y; Park, K | 1 |
| Bonzo, JA; Gonzalez, FJ; Krausz, KW; Patterson, AD | 1 |
| Gosmanov, AR; Umpierrez, GE; Westerhaus, B | 1 |
| Bell, PM; Cuthbertson, J; O'Harte, FP; Patterson, S | 1 |
| Bellomo Damato, A; Giorgino, F; Giorgino, R; Laviola, L; Stefanelli, G | 1 |
| Chung, HS; Jun, HJ; Kim, MK; Kim, TK; Ko, JH; Kwon, MJ; Lee, SH; Oh, MK; Park, JH; Rhee, BD; Suk, JH; Yoon, CS | 1 |
| Blanco, H; Góõmez, MP; Laguna, JJ; Rojas, P; Sánchez, L; Santos, A | 1 |
| Hirose, T; Kudo, K | 1 |
| Grunberger, G | 1 |
| Guo, H; Li, L; Li, Z; Liao, Y; Liu, H; Pan, H; Yan, X; Yang, G; Yang, M | 1 |
| Abdelmoneim, AS; Brocks, DR; Hasenbank, SE; Light, PE; Seubert, JM; Simpson, SH | 1 |
| Fatehi, M; Lang, VY; Light, PE | 1 |
| Adams, SH | 1 |
| Aay, N; Aoyama, R; Arcalas, A; Bentzien, F; Cancilla, B; Chan, V; Du, H; Finn, P; Galan, A; Hanel, A; Harrison, A; Kearney, P; Koltun, ES; Lamb, P; Larson, CJ; Mohan, R; Nachtigall, J; Nuss, J; Ogilvie, K; Plonowski, A; Qian, F; Richards, S; Rosen, J; Tam, D; Wang, T; Won, KA; Yakes, M; Zhang, J; Zhang, W | 1 |
| Burd, NA; Dendale, P; Dirks, ML; Hansen, D; Snijders, T; van Loon, LJ; Verdijk, LB; Vranckx, P; Wall, BT | 1 |
| Mita, T; Watada, H | 1 |
| Du, X; Duquette, J; Fu, A; Houze, J; Li, L; Liu, J; Lizarzaburu, M; Medina, JC; Murakoshi, M; Nara, F; Oda, K; Okuyama, R; Reagan, J; Turcotte, S; Yu, M | 1 |
| Chen, X; Du, X; Fan, P; Fu, A; Fu, Z; Houze, J; Kim, YJ; Lai, S; Li, L; Liu, Q; Lizarzaburu, M; Medina, JC; Motani, A; Murakoshi, M; Nara, F; Oda, K; Okuyama, R; Reagan, JD; Shen, W; Turcotte, S; Xiong, Y; Zhang, Y | 1 |
| Chen, M; Guo, Z; Hao, J; Houze, J; Lin, DC; Lopez, E; Luo, J; Ma, Z; Nguyen, K; Rulifson, IC; Tian, B; Tian, L; Tran, T; Wang, Y; Zhang, Y | 1 |
| Adamski, J; Boeing, H; Drogan, D; Floegel, A; Fritsche, A; Häring, HU; Hrabě de Angelis, M; Illig, T; Joost, HG; Mühlenbruch, K; Peters, A; Pischon, T; Prehn, C; Roden, M; Schulze, MB; Stefan, N; Wang-Sattler, R; Yu, Z | 1 |
| Chen, L; Dong, XC; Jones, DR; Liu, S; Shen, W; Tao, R; Wang, L; Wei, D; Yu, ZH; Zhang, S; Zhang, ZY | 1 |
| Raleigh, DP; Tu, LH | 1 |
| Wang, L; Yang, JK | 1 |
| Bigelow, M; Halvatsiotis, P; Nair, KS; Short, KR | 1 |
| Foley, JE; Gatlin, MR; Rosenstock, J; Shen, SG | 1 |
| Ball, M; Dickinson, S; Hershon, K; Holmes, D; Saloranta, C | 1 |
| Davies, MJ | 1 |
| Kikuchi, M; Notoya, Y | 1 |
| Shiba, T | 1 |
| Ito, S; Kitahara, Y; Mine, T; Miura, K; Takesue, K; Uchida, Y; Wada, R; Yagihashi, S | 1 |
| Göke, B; Parhofer, KG | 1 |
| Caro, J; Salas, M; Ward, A | 1 |
| Iizuka, K; Imamura, M; Mori, M; Nagai, T | 1 |
| Keizer, HA; Kruijshoop, M; Menheere, PP; Saris, WH; van Loon, LJ; Wagenmakers, AJ | 1 |
| Devineni, D; Lee, JS; McLeod, JF; Prasad, P; Smith, HT; Walter, YH | 1 |
| Chandrasekharan, S; Desai, A; Ganesan, R; Jain, SD; Jayaram, S; Rao, PP | 1 |
| Caminos, QR; Chacín, LF; de la Torre, W; Islas-Andrade, S; López, G; Martínez de Hurtado, E; Revilla-Monsalve, MC; Yupanqui, H | 1 |
| Foley, JE; Fonseca, V; Grunberger, G; Gupta, S; Shen, S | 1 |
| Hale, PM; Hollander, P; Khutoryansky, N; Klaff, L; McGill, J; Raskin, P; South, SA | 1 |
| Del Prato, S; Emmons, RP; Guitard, C; Heine, RJ; Keilson, L; Shen, SG | 1 |
| Yamada, K | 1 |
| Odawara, M | 1 |
| Sevinc, A | 1 |
| Inoue, T; Itahana, R; Izumi, M; Miyagawa, K; Nakanishi, T; Shibahara, N; Takamitsu, Y | 1 |
| Lehwalder, D; Schandry, R; Schatz, H; Schoppel, K | 1 |
| Bell, PM; Flatt, PR; Lindsay, JR; McKillop, AM; Mooney, MH; O'Harte, FP | 1 |
| Carroll, MF; Castro, M; Gutierrez, A; Schade, DS; Tsewang, D | 1 |
| Yoshida, T; Yoshikawa, T; Yoshioka, K | 1 |
| Baron, MA | 1 |
| Bailey, CJ; Flatt, PR; Gault, VA; Green, BD; Greer, B; Harriott, P; Irwin, N; Mooney, MH; O'Harte, FP | 1 |
| Anderson, DM; Barnett, AH; Morgan, R; Owens, DR; Shelley, S | 1 |
| McLeod, JF | 1 |
| Haslbeck, M; Jakob, S; Kellerer, M; Linn, T | 1 |
| Abrahamian, H; Dzien, A; Francesconi, M; Loiskandl, A; Prager, R; Weitgasser, R | 1 |
| Kitahara, Y; Miura, K; Mori, Y; Tajima, N | 1 |
| Bentley, L; Browne, M; Cox, RD; Goldsworthy, M; Haynes, A; Hough, T; Hugill, A; Hunter, AJ; Mijat, V; Moir, L; Quarterman, J; Spurr, N; Toye, AA | 1 |
| Brazinsky, SA; Farrell, J; Hale, PM; Hassman, DR; Khutoryansky, N; Madder, RD; Rosenstock, J | 1 |
| Baron, MA; Foley, JE; Horton, ES; Shen, SG | 1 |
| Boutati, E; Brunel, P; Dimitriadis, G; Lambadiari, V; Maratou, E; Mitrou, P; Raptis, SA | 1 |
| Dominic, EA; Ferrando, A; Raj, DS; Waters, D; Welbourne, T; Wolfe, R | 1 |
| Atkin, SL; Robertson, D; Weaver, JU | 1 |
| Higa, N; Shimabukuro, M; Tagawa, T; Takasu, N; Ueda, S | 1 |
| Gall, MA; Lammert, M; Minshall, ME; Nicklasson, L; Palmer, AJ; Roze, S; Spinas, GA; Valentine, WJ | 1 |
| Kawamori, R; Miwa, S; Ohmura, C; Tanaka, Y; Watada, H | 1 |
| Baron, MA; Cefalu, W; Fonseca, VA; Gerich, JE; Hsia, S; Kelley, DE; Nestler, JE; Purkayastha, D | 1 |
| Kitahara, Y; Mine, T; Miura, K; Mori, Y; Tajima, N | 1 |
| Efrat, S; Gazit, E; Mazor, Y; Porat, Y | 1 |
| Blackburn, GL | 1 |
| Ashokkumar, N; Pari, L | 2 |
| Abletshauser, C; Bengel, FM; Nekolla, SG; Neverve, J; Schnell, O; Schwaiger, M; Standl, E | 1 |
| Kuriyama, G; Mori, Y; Tajima, N | 1 |
| Hirose, T | 3 |
| Tsujii, S | 1 |
| Kawamori, R | 1 |
| Li, JW; Tian, HM; Wang, JN; Yu, HL; Zhang, XX; Zhao, GZ | 1 |
| Ferrannini, E; Foley, JE; Gastaldelli, A; Mari, A; Pratley, RE | 1 |
| Anastasopoulou, I; Boutati, E; Karafoullidou, A; Karambakalis, N; Katsilambros, N; Kyriaki, D; Lourida, E; Perea, D; Perrea, D; Raptis, SA; Tentolouris, N; Tselepis, AD; Tsoukala, C | 1 |
| Malaisse, WJ | 1 |
| Kanda, K; Kishikawa, H; Okada, Y; Tanaka, Y | 1 |
| Koopman, R; Manders, RJ; Menheere, PP; Saris, WH; Schaper, NC; van Loon, LJ; Wagenmakers, AJ; Zorenc, AH | 1 |
| Iida, M; Iwase, M; Nakamura, U; Nohara, S; Sasaki, N; Sonoki, K; Uchizono, Y | 1 |
| Baron, MA; Gerich, J; Jean-Louis, L; Purkayastha, D; Raskin, P | 1 |
| Campbell, IW | 1 |
| Gorogawa, S; Hazama, Y; Hori, M; Kaneto, H; Kato, K; Kawamori, D; Matsuhisa, M; Nakamura, Y; Ohtoshi, K; Shiraiwa, T; Yamasaki, Y; Yoshiuchi, K | 1 |
| Biró, Z; Ludány, A; Molnár, GA; Nemes, V; Wagner, Z; Wittmann, I | 1 |
| Groop, LC; Honkanen, EH; Isomaa, B; Sarelin, L; Tuomi, T | 1 |
| Hirose, T; Kawamori, R; Kawasumi, M; Kurebayashi, S; Tanaka, Y; Watada, H | 1 |
| Campbell, A | 1 |
| Ai, M; Ogita, K; Shimokado, K; Tanaka, A | 1 |
| Ahrén, B; Axelsen, M; Jansson, PA; Johanson, EH; Sandqvist, M; Schmelz, M; Smith, U | 1 |
| Beconi, M; Di Salvo, J; Edmondson, SD; Eiermann, GJ; Harper, B; He, H; He, J; Leiting, B; Leone, JF; Levorse, DA; Lyons, K; Mastracchio, A; Mathvink, RJ; Park, YJ; Patel, RA; Patel, SB; Petrov, A; Roy, RS; Scapin, G; Shang, J; Smith, A; Thornberry, NA; Weber, AE; Wu, JK; Xu, S; Zhu, B | 1 |
| Aoyagi, I; Fujimori, Y; Fuujimori, Y; Itoh, Y; Kojima, M; Kojima, S; Kusama, H; Mori, Y; Ojima, K; Shibata, N; Tajima, N; Yamazaki, Y | 1 |
| Collober-Maugeais, C; Cressier, F; Pecher, E; Ristic, S | 1 |
| Harada, S; Ito, S; Nakaya, Y; Nomura, M | 1 |
| Chai, J; Hu, QH; Li, HY; Li, MZ; Liang, Z; Luo, GC; Yan, DW | 1 |
| Albrecht, H; Hug, H; Kersten, S; Meyer, UA; Podvinec, M; Roth, A; Rücker, C; Scarsi, M; Schwede, T | 1 |
| Ashwell, SG; Dashora, UK; Home, PD; Sibal, L | 1 |
| Gao, HW; Hong, TP; Lin, YJ; Wang, HN; Xie, C | 1 |
| Black, C; Donnelly, P; McIntyre, L; Royle, PL; Shepherd, JP; Thomas, S | 1 |
| Collober-Maugeais, C; Cressier, F; Pecher, E; Ristic, S; Tang, P | 1 |
| Huang, L; Li, J; Li, Q; Li, Y; Liang, J; Liu, Y; Luo, R; Ni, Z; Tian, H; Wang, N; Wu, T; Yu, H | 1 |
| Choi, JB; Hirose, T; Kawamori, R; Mita, T; Sato, F; Shimizu, T; Tamura, Y; Tanaka, Y; Watada, H; Watanabe, T | 1 |
| Layton, D; Shakir, SA; Twaites, B; Wilton, LV | 1 |
| Baron, MA; Gerich, JE; Jean-Louis, L; Marcellari, A; Purkayastha, D; Schwarz, SL | 1 |
| Bryant, SM; Sherk, DK | 1 |
| Atsumi, Y; Funae, O; Kawai, T; Nakamura, Y; Oikawa, Y; Shimada, A; Suzuki, R; Watanabe, M; Yajima, K; Yamada, S | 1 |
| Katsilambros, N; Tentolouris, N; Voulgari, C | 1 |
| González-Clemente, JM | 1 |
| Gupta, R; Marek, P; Raleigh, DP | 1 |
| Chen, L; Ding, GX; Guo, Y; Hou, WK; Hu, GL; Ji, QH; Li, QF; Li, YX; Luo, R; Wang, H; Wang, PN; Wang, SJ; Zhang, NY; Zhang, YP | 1 |
| Baron, AD; Brechtel, G; Denne, SC; Johnson, A; Liechty, EA | 1 |
| Biolo, G; Bruttomesso, D; Fongher, C; Inchiostro, S; Panebianco, G; Tessari, P; Tiengo, A; Vedovato, M | 1 |
| Hua, QX; Inouye, K; Shoelson, SE; Weiss, MA | 1 |
| Bier, D; Bucci, A; Dailey, G; Gerich, J; Jansson, PA; Jenssen, T; Nurjhan, N; Perriello, G; Stumvoll, M; Welle, S | 1 |
| Kikuchi, M | 3 |
| Ladrière, L; Laghmich, A; Malaisse, WJ; Malaisse-Lagae, F | 1 |
| Kondo, N | 1 |
| Ishikawa, Y; Takagi, Y; Takeno, H; Tani, T; Watanabe, K | 1 |
| Ikemoto, T; Ishikawa, Y; Saito, MN; Takeno, H; Tani, T; Watanabe, K | 1 |
| Ishikawa, Y; Takeno, H; Tani, T; Watanabe, K | 1 |
| Smits, P; Tack, CJ | 1 |
| Keilson, L; Mather, S; McLeod, JF; Subramanian, S; Walter, YH | 1 |
| Clark, PM; Nattrass, M; Smith, JM; Whitelaw, DC | 1 |
| Bouter, KP; Dickinson, S; Guitard, C; Hanefeld, M | 1 |
| Hirschberg, Y; Karara, AH; McLeod, JF; Pietri, AO | 1 |
| Garreffa, S; McLeod, JF; Spratt, DI; Walter, YH | 1 |
| Füchtenbusch, M; Schatz, H; Standl, E | 1 |
| Dunn, CJ; Faulds, D | 1 |
| Ikenoue, T; Kondo, N | 1 |
| Clinkingbeard, C; Foley, J; Gatlin, M; Horton, ES; Mallows, S; Shen, S | 1 |
| Landgraf, R | 1 |
| Kawamori, R; Nishiyama, K; Niwa, M; Shimizu, T; Uchino, H | 1 |
| Lieder, TR | 1 |
| Chen, W; de Souza, CJ; Dragonas, N; Gagen, K | 1 |
| Dunning, BE; Foley, JE; Gatlin, MR; Haas, SJ; Hollander, PA; Schwartz, SL; Zheng, H | 1 |
| Gribble, FM; Levy, JC; Manley, SE | 1 |
| Aljada, A; Assian, E; Dandona, P; Garg, R; Ghanim, H; Hamouda, W; Mohanty, P | 1 |
| Halas, CJ | 1 |
| Dunning, BE; Foley, JE; Pratley, RE | 1 |
| Abe, T; Mori, T; Nagai, Y; Nomura, G | 1 |
| Hanif, W; Kumar, S | 1 |
| Anderson, DM; Luzio, SD; Owens, DR | 1 |
| Baker, DE; Campbell, RK; Levien, TL; White, JR | 1 |
| Dornhorst, A | 1 |
| Devineni, D; Foley, JE; Horowitz, A; Howell, W; Hsu, CH; Kahn, SE; Ligueros-Saylan, M; McLeod, JF; Montgomery, B | 1 |
| Yudkin, JS | 1 |
| Nelson, G | 1 |
| Andrews, J | 1 |
| Ahmann, AJ; Riddle, MC | 1 |
| Ball, M; Guitard, C; Marre, M; Usadel, KH; Van Gaal, L; Whatmough, I | 1 |
| Kotapati, S | 1 |
| Biolo, G; Bruttomesso, D; Fongher, C; Fratton, MG; Inchiostro, S; Panebianco, G; Sabadin, L; Tessari, P; Tiengo, A | 1 |
| Filer, LJ; Stegink, LD | 1 |
53 review(s) available for phenylalanine and Diabetes Mellitus, Adult-Onset
| Article | Year |
|---|---|
Development of pharmacogenomic algorithm to optimize nateglinide dose for the treatment of type 2 diabetes mellitus.
Topics: Algorithms; Area Under Curve; Aryl Hydrocarbon Hydroxylases; Cyclohexanes; Cytochrome P-450 CYP2C9; Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Liver-Specific Organic Anion Transporter 1; Nateglinide; Pharmacogenetics; Phenylalanine | 2022 |
Pathophysiology, Differential Diagnosis, and Treatment of Diabetic Diarrhea.
Topics: Antidiarrheals; Autonomic Nervous System Diseases; Blind Loop Syndrome; Celiac Disease; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Diabetic Neuropathies; Diagnosis, Differential; Diarrhea; Diphenoxylate; Enteric Nervous System; Exocrine Pancreatic Insufficiency; Gastrointestinal Agents; Gastrointestinal Motility; Hypoglycemic Agents; Imidazoles; Inflammation; Inflammatory Bowel Diseases; Interstitial Cells of Cajal; Intestinal Absorption; Intestinal Mucosa; Irritable Bowel Syndrome; Loperamide; Neuroglia; Non-Nutritive Sweeteners; Oxidative Stress; Phenylalanine; Serotonin 5-HT3 Receptor Antagonists | 2019 |
Peptidyl and Non-Peptidyl Oral Glucagon-Like Peptide-1 Receptor Agonists.
Topics: Diabetes Mellitus, Type 2; Glucagon-Like Peptide-1 Receptor; Humans; Hypoglycemic Agents; Isoquinolines; Phenylalanine; Pyridines | 2021 |
The journey from gene knockout to clinical medicine: telotristat and sotagliflozin.
Topics: Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Enzyme Inhibitors; Gene Knockout Techniques; Glucose; Glycosides; Humans; Hypoglycemic Agents; Phenylalanine; Pyrimidines; Serotonin; Sodium-Glucose Transporter 1; Sodium-Glucose Transporter 2; Tryptophan Hydroxylase | 2019 |
Pharmacogenomics of glinides.
Topics: Carbamates; Cyclohexanes; Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Inactivation, Metabolic; Insulin; Insulin Secretion; Insulin-Secreting Cells; Isoindoles; KATP Channels; Nateglinide; Pharmacogenetics; Phenylalanine; Piperidines | 2015 |
Impact of glucose-lowering drugs on cardiovascular disease in type 2 diabetes.
Topics: Carbamates; Clinical Trials as Topic; Coronary Artery Disease; Cyclohexanes; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Dipeptidyl-Peptidase IV Inhibitors; Glucagon-Like Peptide-1 Receptor; Glycoside Hydrolase Inhibitors; Humans; Hypoglycemic Agents; Insulin; Metformin; Nateglinide; Phenylalanine; Piperidines; Sodium-Glucose Transport Proteins; Sulfonylurea Compounds; Thiazolidinediones; Treatment Outcome | 2015 |
Role of insulin in the regulation of human skeletal muscle protein synthesis and breakdown: a systematic review and meta-analysis.
Topics: Diabetes Mellitus, Type 2; Humans; Insulin; Insulin Resistance; Muscle Proteins; Muscle, Skeletal; Phenylalanine; Signal Transduction | 2016 |
Insulin secretagogues for prevention or delay of type 2 diabetes mellitus and its associated complications in persons at increased risk for the development of type 2 diabetes mellitus.
Topics: Adult; Benzamides; Blood Glucose; Cardiovascular Diseases; Cyclohexanes; Diabetes Mellitus, Type 2; Fasting; Humans; Hypoglycemic Agents; Insulin; Insulin Secretion; Metformin; Middle Aged; Nateglinide; Phenylalanine; Randomized Controlled Trials as Topic; Sulfonylurea Compounds | 2016 |
Drugs for type 2 diabetes.
Topics: alpha-Galactosidase; Biguanides; Carbamates; Cyclohexanes; Diabetes Mellitus, Type 2; Drug Combinations; Drug Therapy, Combination; Humans; Hypoglycemic Agents; Insulin; Nateglinide; Phenylalanine; Piperidines; Pyrazines; Sitagliptin Phosphate; Sulfonylurea Compounds; Thiazolidinediones; Triazoles | 2008 |
Nateglinide versus repaglinide for type 2 diabetes mellitus in China.
Topics: Carbamates; China; Cyclohexanes; Diabetes Mellitus, Type 2; Female; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Male; Middle Aged; Nateglinide; Phenylalanine; Piperidines | 2009 |
Safety and efficacy of nateglinide/metformin combination therapy in the treatment of type 2 diabetes.
Topics: Blood Glucose; Clinical Trials as Topic; Cyclohexanes; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Metformin; Nateglinide; Phenylalanine; Treatment Outcome | 2008 |
Advances in oral therapy for type 2 diabetes.
Topics: Acarbose; Administration, Oral; Blood Glucose; Carbamates; Cyclohexanes; Diabetes Mellitus, Type 2; Drug Combinations; Drug Therapy, Combination; Glycated Hemoglobin; Humans; Hypoglycemia; Hypoglycemic Agents; Insulin; Insulin Secretion; Insulin-Secreting Cells; Metformin; Nateglinide; Phenylalanine; Piperidines; Randomized Controlled Trials as Topic; Thiazolidinediones; United States; Weight Gain | 2000 |
Diabetes prevention: can insulin secretagogues do the job?
Topics: Benzamides; Blood Glucose; Cyclohexanes; Diabetes Mellitus, Type 2; Disease Progression; Evidence-Based Medicine; Humans; Hypoglycemic Agents; Insulin; Insulin Resistance; Nateglinide; Phenylalanine; Preventive Health Services; Sulfonylurea Compounds; Treatment Outcome | 2011 |
[Sulfonylureas and glinides].
Topics: Cyclohexanes; Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Metabolic Syndrome; Nateglinide; Phenylalanine; Sulfonylurea Compounds | 2011 |
Quo vadis nateglinide? Ten-year perspective.
Topics: Animals; Blood Glucose; Clinical Trials, Phase II as Topic; Cyclohexanes; Diabetes Mellitus, Type 2; Humans; Hyperglycemia; Hypoglycemic Agents; Nateglinide; Phenylalanine; Randomized Controlled Trials as Topic | 2011 |
Variations in tissue selectivity amongst insulin secretagogues: a systematic review.
Topics: Animals; ATP-Binding Cassette Transporters; Carbamates; Cardiovascular Diseases; Cricetinae; Cyclohexanes; Diabetes Mellitus, Type 2; Gliclazide; Glipizide; Glyburide; Humans; Hypoglycemic Agents; Ischemic Preconditioning, Myocardial; Isoindoles; Mice; Muscle, Smooth, Vascular; Myocytes, Cardiac; Nateglinide; Phenylalanine; Piperidines; Potassium Channels, Inwardly Rectifying; Rats; Receptors, Drug; Risk Factors; Sulfonylurea Compounds; Sulfonylurea Receptors; Tolbutamide | 2012 |
Emerging perspectives on essential amino acid metabolism in obesity and the insulin-resistant state.
Topics: 3-Methyl-2-Oxobutanoate Dehydrogenase (Lipoamide); Amino Acids, Aromatic; Amino Acids, Sulfur; Animals; Cysteine; Cystine; Diabetes Mellitus, Type 2; Humans; Insulin Resistance; Methionine; Models, Biological; Obesity; Oxidation-Reduction; Oxidative Stress; Phenylalanine; Transaminases; Tyrosine | 2011 |
Insulin secretagogues.
Topics: Carbamates; Cyclohexanes; Diabetes Mellitus, Type 2; Glycated Hemoglobin; Humans; Hyperglycemia; Hyperinsulinism; Hypoglycemic Agents; Insulin; Insulin Secretion; Islets of Langerhans; Nateglinide; Phenylalanine; Piperidines; Postprandial Period; Sulfonylurea Compounds; United Kingdom | 2002 |
[Nateglinide].
Topics: Animals; Blood Glucose; Cyclohexanes; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Glycated Hemoglobin; Humans; Hypoglycemia; Hypoglycemic Agents; Insulin; Insulin Secretion; Nateglinide; Phenylalanine | 2002 |
[Metformin--its regimen and effects].
Topics: Acarbose; Biguanides; Clinical Trials as Topic; Cyclohexanes; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Humans; Hypoglycemic Agents; Insulin; Metformin; Nateglinide; Patient Selection; Phenylalanine; Sulfonylurea Compounds; Treatment Outcome | 2002 |
Treatment of patients over 64 years of age with type 2 diabetes: experience from nateglinide pooled database retrospective analysis.
Topics: Aged; Blood Glucose; Body Mass Index; Comorbidity; Cyclohexanes; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Glyburide; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Metformin; Nateglinide; Phenylalanine; Randomized Controlled Trials as Topic; Retrospective Studies | 2003 |
[Pharmacological treatment of postprandial hyperglycemia in hypertensive patients with type 2 diabetes mellitus].
Topics: Acarbose; Cyclohexanes; Diabetes Complications; Diabetes Mellitus; Diabetes Mellitus, Type 2; Enzyme Inhibitors; Glycoside Hydrolase Inhibitors; Humans; Hyperglycemia; Hypertension; Hypoglycemic Agents; Inositol; Insulin Resistance; Nateglinide; Obesity; Phenylalanine; Postprandial Period | 2003 |
[Nateglinide and mitiglinide].
Topics: Cardiovascular Diseases; Cyclohexanes; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Humans; Hyperglycemia; Hypoglycemic Agents; Indoles; Insulin; Insulin Resistance; Insulin Secretion; Isoindoles; Metformin; Nateglinide; Phenylalanine; Postprandial Period; Stimulation, Chemical | 2003 |
[symbol: see text] Nateglinide and [symbol: see text] repaglinide for type 2 diabetes?
Topics: Carbamates; Cyclohexanes; Diabetes Mellitus, Type 2; Double-Blind Method; Humans; Hypoglycemic Agents; Nateglinide; Phenylalanine; Piperidines; Randomized Controlled Trials as Topic; Treatment Outcome | 2003 |
Clinical pharmacokinetics of nateglinide: a rapidly-absorbed, short-acting insulinotropic agent.
Topics: Area Under Curve; Biological Availability; Clinical Trials as Topic; Cyclohexanes; Diabetes Mellitus, Type 2; Drug Interactions; Food; Half-Life; Humans; Hypoglycemic Agents; Insulin; Insulin Secretion; Liver; Metabolic Clearance Rate; Nateglinide; Phenylalanine; Protein Binding; Structure-Activity Relationship; Tissue Distribution | 2004 |
[Continuation 50. Type 2 diabetes: possibilities and limitations of pharmacological therapy].
Topics: 1-Deoxynojirimycin; Acarbose; Aged; Blood Glucose; Carbamates; Contraindications; Cyclohexanes; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Enzyme Inhibitors; Fasting; Follow-Up Studies; Germany; Glucosamine; Glyburide; Glycated Hemoglobin; Glycoside Hydrolase Inhibitors; Humans; Hypoglycemia; Hypoglycemic Agents; Imino Pyranoses; Insulin; Metformin; Middle Aged; Nateglinide; Obesity; Patient Compliance; Phenylalanine; Pioglitazone; Piperidines; Practice Guidelines as Topic; Risk Factors; Rosiglitazone; Sulfonylurea Compounds; Thiazolidinediones; Time Factors | 2003 |
[Effects of nateglinide in impaired glucose tolerance subjects].
Topics: Cardiovascular Diseases; Clinical Trials as Topic; Cyclohexanes; Diabetes Mellitus, Type 2; Glucose Intolerance; Humans; Hyperglycemia; Hypoglycemic Agents; Insulin; Insulin Resistance; Insulin Secretion; Nateglinide; Obesity; Phenylalanine; Postprandial Period; Risk Factors | 2005 |
[NAVIGATOR trial (nateglinide)].
Topics: Cardiovascular Diseases; Cyclohexanes; Diabetes Mellitus, Type 2; Endpoint Determination; Glucose Intolerance; Humans; Hypoglycemic Agents; Insulin; Insulin Resistance; Insulin Secretion; Life Style; Nateglinide; Phenylalanine; Primary Prevention; Randomized Controlled Trials as Topic; Risk | 2005 |
[Therapies for newly-onset diabetic patients].
Topics: Acarbose; Cyclohexanes; Diabetes Mellitus, Type 2; Diet Therapy; Enzyme Inhibitors; Exercise Therapy; Glucose; Glucose Intolerance; Glycogen; Glycoside Hydrolase Inhibitors; Humans; Hypoglycemic Agents; Insulin; Insulin Resistance; Insulin Secretion; Metformin; Nateglinide; Phenylalanine; Sulfonylurea Compounds; Thiazolidinediones | 2005 |
Pharmacology of the meglitinide analogs: new treatment options for type 2 diabetes mellitus.
Topics: Animals; Benzamides; Carbamates; Cyclohexanes; Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Nateglinide; Phenylalanine; Piperidines | 2003 |
Nateglinide--current and future role in the treatment of patients with type 2 diabetes mellitus.
Topics: Blood Glucose; Cyclohexanes; Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Insulin; Nateglinide; Phenylalanine | 2005 |
[Significance of insulin secretion pattern lectured by "glinides" in the treatment of postprandial hyperglycemia].
Topics: Cyclohexanes; Diabetes Mellitus, Type 2; Eating; Humans; Hyperglycemia; Hypoglycemic Agents; Indoles; Insulin; Insulin Secretion; Isoindoles; Nateglinide; Phenylalanine | 2005 |
Glycaemic control in type 2 diabetes.
Topics: Adult; Blood Glucose; Blood Glucose Self-Monitoring; Cyclohexanes; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Humans; Hypoglycemic Agents; Insulin; Metformin; Nateglinide; Patient Education as Topic; Phenylalanine; Sulfonylurea Compounds | 2005 |
Meglitinide analogues for type 2 diabetes mellitus.
Topics: Benzamides; Carbamates; Cyclohexanes; Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Metformin; Nateglinide; Phenylalanine; Piperidines; Randomized Controlled Trials as Topic | 2007 |
[Sulfonylureas and glinides].
Topics: Cyclohexanes; Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Metabolic Syndrome; Nateglinide; Phenylalanine; Sulfonylurea Compounds | 2006 |
A review of nateglinide in the management of patients with type 2 diabetes.
Topics: Cyclohexanes; Diabetes Mellitus, Type 2; Fasting; Humans; Hypoglycemic Agents; Insulin; Insulin Secretion; KATP Channels; Nateglinide; Phenotype; Phenylalanine; Postprandial Period | 2007 |
Modulation of insulin secretion in non-insulin-dependent diabetes mellitus by two novel oral hypoglycaemic agents, NN623 and A4166.
Topics: Administration, Oral; Biological Availability; Blood Glucose; Carbamates; Cyclohexanes; Diabetes Mellitus, Type 2; Glyburide; Humans; Hypoglycemic Agents; Insulin; Insulin Secretion; Intestinal Absorption; Molecular Structure; Nateglinide; Phenylalanine; Piperidines; Reference Values; Stereoisomerism | 1996 |
[Preclinical studies of AY4166 (A-4166)].
Topics: Animals; Blood Glucose; Cyclohexanes; Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Insulin; Insulin Secretion; Nateglinide; Phenylalanine | 1997 |
[Clinical trial of AY4166].
Topics: Clinical Trials, Phase II as Topic; Cyclohexanes; Diabetes Mellitus, Type 2; Eating; Humans; Hypoglycemic Agents; Insulin; Insulin Secretion; Nateglinide; Phenylalanine; Time Factors | 1997 |
[Non-SU, insulin secretagogues].
Topics: Cyclohexanes; Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Indoles; Isoindoles; Nateglinide; Phenylalanine | 1999 |
New drugs for diabetes.
Topics: Carbamates; Chromans; Cyclohexanes; Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Insulin Resistance; Metformin; Nateglinide; Phenylalanine; Piperidines; Thiazoles; Thiazolidinediones; Troglitazone | 1999 |
Clinical efficacy of new thiazolidinediones and glinides in the treatment of type 2 diabetes mellitus.
Topics: Carbamates; Cyclohexanes; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Nateglinide; Phenylalanine; Pioglitazone; Piperidines; Rosiglitazone; Thiazoles; Thiazolidinediones | 2000 |
Nateglinide.
Topics: Administration, Oral; Clinical Trials as Topic; Cyclohexanes; Diabetes Mellitus, Type 2; Humans; Hypercalcemia; Hypoglycemic Agents; Insulin; Insulin Secretion; Nateglinide; Pancreas; Phenylalanine | 2000 |
[Pharmacological properties of nateglinide, rapid-onset/short-duration insulinotropic agent, in the treatment of type 2 diabetes].
Topics: Animals; Cyclohexanes; Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Insulin; Insulin Secretion; Nateglinide; Phenylalanine | 2000 |
Meglitinide analogues in the treatment of type 2 diabetes mellitus.
Topics: Benzamides; Carbamates; Cyclohexanes; Diabetes Mellitus, Type 2; Glyburide; Humans; Hypoglycemic Agents; Molecular Structure; Nateglinide; Phenylalanine; Piperidines | 2000 |
Nateglinide.
Topics: Biological Availability; Blood Glucose; Cyclohexanes; Diabetes Mellitus, Type 2; Drug Administration Schedule; Half-Life; Humans; Hypoglycemic Agents; Male; Nateglinide; Phenylalanine; Randomized Controlled Trials as Topic | 2001 |
Rapid acting insulinotropic agents: restoration of early insulin secretion as a physiologic approach to improve glucose control.
Topics: Animals; Carbamates; Cyclohexanes; Diabetes Mellitus, Type 2; Glucose; Guanidines; Humans; Hypoglycemic Agents; Indoles; Insulin; Insulin Secretion; Isoindoles; Nateglinide; Phenylalanine; Piperidines | 2001 |
Nateglinide: a new rapid-acting insulinotropic agent.
Topics: Animals; Clinical Trials as Topic; Cyclohexanes; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Guidelines as Topic; Humans; Hyperglycemia; Hypoglycemic Agents; Metformin; Microcirculation; Molecular Structure; Nateglinide; Phenylalanine; Postprandial Period | 2001 |
Nateglinide therapy for type 2 diabetes mellitus.
Topics: Animals; Clinical Trials as Topic; Cyclohexanes; Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Nateglinide; Phenylalanine | 2001 |
Insulinotropic meglitinide analogues.
Topics: Adult; Animals; Benzamides; Carbamates; Cyclohexanes; Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Insulin; Insulin Secretion; Nateglinide; Phenylalanine; Piperidines; Rats | 2001 |
Restoring post-prandial insulin release in type 2 diabetes.
Topics: Blood Glucose; Clinical Trials as Topic; Cyclohexanes; Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Insulin; Insulin Secretion; Metformin; Nateglinide; Phenylalanine; Postprandial Period | 2002 |
Current oral agents for type 2 diabetes. Many options, but which to choose when?
Topics: Carbamates; Cyclohexanes; Diabetes Mellitus, Type 2; Drug Monitoring; Drug Therapy, Combination; Glycoside Hydrolases; Humans; Hypoglycemic Agents; Metformin; Nateglinide; Phenylalanine; Piperidines; Receptors, Cytoplasmic and Nuclear; Sulfonylurea Compounds; Transcription Factors | 2002 |
Nateglinide, a new agent for postprandial glucose control in type 2 diabetes.
Topics: Blood Glucose; Clinical Trials as Topic; Cyclohexanes; Diabetes Mellitus, Type 2; Drug Interactions; Humans; Hypoglycemic Agents; Nateglinide; Phenylalanine | 2002 |
80 trial(s) available for phenylalanine and Diabetes Mellitus, Adult-Onset
| Article | Year |
|---|---|
Altered Caffeine Metabolism Is Associated With Recurrent Hypoglycemia in Type 2 Diabetes Mellitus: A UPLC-MS-Based Untargeted Metabolomics Study.
Topics: Biomarkers; Caffeine; Case-Control Studies; Chromatography, High Pressure Liquid; Chromatography, Liquid; Cortisone; Diabetes Mellitus, Type 2; Humans; Hypoglycemia; Phenylalanine; Tandem Mass Spectrometry | 2022 |
Effects of pioglitazone versus glimepiride exposure on hepatocellular fat content in type 2 diabetes.
Topics: Adiponectin; Blood Glucose; Body Mass Index; C-Reactive Protein; Cyclohexanes; Diabetes Mellitus, Type 2; Double-Blind Method; Female; Glycated Hemoglobin; Hepatocytes; Humans; Hypoglycemic Agents; Insulin; Insulin Resistance; Lipid Metabolism; Lipolysis; Male; Middle Aged; Nateglinide; Phenylalanine; Pioglitazone; Sulfonylurea Compounds; Thiazolidinediones; Treatment Outcome | 2013 |
Nateglinide and acarbose are comparably effective reducers of postprandial glycemic excursions in chinese antihyperglycemic agent-naive subjects with type 2 diabetes.
Topics: Acarbose; Adolescent; Adult; Antihypertensive Agents; Area Under Curve; Blood Glucose; China; Cyclohexanes; Diabetes Mellitus, Type 2; Female; Glycated Hemoglobin; Glycemic Index; Humans; Hypertension; Hypoglycemic Agents; Male; Middle Aged; Nateglinide; Phenylalanine; Postprandial Period; Prospective Studies; Treatment Outcome | 2013 |
Incidence of atrial fibrillation in a population with impaired glucose tolerance: the contribution of glucose metabolism and other risk factors. A post hoc analysis of the Nateglinide and Valsartan in Impaired Glucose Tolerance Outcomes Research trial.
Topics: Aged; Atrial Fibrillation; Blood Glucose; Cyclohexanes; Diabetes Mellitus, Type 2; Double-Blind Method; Female; Glucose Intolerance; Humans; Hypoglycemic Agents; Incidence; Male; Middle Aged; Nateglinide; Outcome Assessment, Health Care; Phenylalanine; Proportional Hazards Models; Risk Assessment; Risk Factors; Tetrazoles; Valine; Valsartan | 2013 |
Differential therapeutic effects of nateglinide and acarbose on fasting and postprandial lipid profiles: a randomized trial.
Topics: Acarbose; Adult; China; Cholesterol, HDL; Cholesterol, LDL; Cyclohexanes; Diabetes Mellitus, Type 2; Dyslipidemias; Fasting; Female; Humans; Hypoglycemic Agents; Lipids; Male; Middle Aged; Nateglinide; Phenylalanine; Postprandial Period; Prospective Studies; Time Factors; Triglycerides | 2015 |
A Pharmacokinetic/Pharmacodynamic Drug-Drug Interaction Study of Tofogliflozin (a New SGLT2 Inhibitor) and Selected Anti-Type 2 Diabetes Mellitus Drugs.
Topics: 1-Deoxynojirimycin; Adult; Benzhydryl Compounds; Cyclohexanes; Diabetes Mellitus, Type 2; Drug Interactions; Glucose; Glucosides; Healthy Volunteers; Humans; Hypoglycemic Agents; Inositol; Male; Metformin; Middle Aged; Nateglinide; Phenylalanine; Pioglitazone; Sitagliptin Phosphate; Sodium-Glucose Transporter 2 Inhibitors; Sulfonylurea Compounds; Thiazolidinediones; Urine; Young Adult | 2016 |
Sodium nitrate co-ingestion with protein does not augment postprandial muscle protein synthesis rates in older, type 2 diabetes patients.
Topics: Aged; Blood Glucose; Carbon Isotopes; Diabetes Mellitus, Type 2; Dietary Proteins; Eating; Glycated Hemoglobin; Humans; Intestinal Absorption; Leucine; Male; Muscle Proteins; Muscle, Skeletal; Myofibrils; Nitrates; Phenylalanine; Postprandial Period; Protein Biosynthesis | 2016 |
Nateglinide may increase high-molecular weight adiponectin in type 2 diabetic patients with hypoadiponectinemia.
Topics: Adiponectin; Aged; Cyclohexanes; Diabetes Mellitus, Type 2; Female; Humans; Hyperglycemia; Hypoglycemic Agents; Insulin; Male; Middle Aged; Molecular Weight; Nateglinide; Phenylalanine | 2008 |
Nateglinide and glibenclamide metabolic effects in naïve type 2 diabetic patients treated with metformin.
Topics: Blood Glucose; Body Mass Index; Cyclohexanes; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Therapy, Combination; Female; Glyburide; Glycated Hemoglobin; Hemodynamics; Homeostasis; Humans; Hypoglycemic Agents; Insulin; Lipids; Male; Metformin; Middle Aged; Nateglinide; Phenylalanine | 2009 |
Nateglinide versus repaglinide for type 2 diabetes mellitus in China.
Topics: Carbamates; China; Cyclohexanes; Diabetes Mellitus, Type 2; Female; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Male; Middle Aged; Nateglinide; Phenylalanine; Piperidines | 2009 |
Nateglinide combination therapy with basal insulin and metformin in patients with Type 2 diabetes.
Topics: Adult; Aged; Cyclohexanes; Diabetes Mellitus, Type 2; Drug Administration Schedule; Drug Therapy, Combination; Female; Glycated Hemoglobin; Humans; Hypoglycemia; Hypoglycemic Agents; Insulin; Male; Metformin; Middle Aged; Nateglinide; Phenylalanine; Postprandial Period; Young Adult | 2009 |
[A comparison of efficacy and tolerance of nateglinide and acarbose monotherapy in type 2 diabetes mellitus].
Topics: Acarbose; Adult; Cyclohexanes; Diabetes Mellitus, Type 2; Double-Blind Method; Female; Follow-Up Studies; Humans; Insulin Resistance; Male; Middle Aged; Nateglinide; Phenylalanine | 2009 |
Insulinotropic actions of nateglinide in type 2 diabetic patients and effects on dipeptidyl peptidase-IV activity and glucose-dependent insulinotropic polypeptide degradation.
Topics: Adamantane; Cyclohexanes; Diabetes Mellitus, Type 2; Dipeptidyl Peptidase 4; Dipeptidyl-Peptidase IV Inhibitors; Female; Gastric Inhibitory Polypeptide; Humans; Insulin; Insulin Secretion; Male; Middle Aged; Nateglinide; Nitriles; Phenylalanine; Pyrrolidines; Vildagliptin | 2009 |
Effect of nateglinide on the incidence of diabetes and cardiovascular events.
Topics: Angiotensin II Type 1 Receptor Blockers; Blood Glucose; Body Weight; Cardiovascular Diseases; Cyclohexanes; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Therapy, Combination; Exercise; Female; Follow-Up Studies; Glucose Intolerance; Humans; Hypoglycemic Agents; Incidence; Kaplan-Meier Estimate; Male; Middle Aged; Nateglinide; Phenylalanine; Proportional Hazards Models; Risk Factors; Tetrazoles; Treatment Failure; Valine; Valsartan | 2010 |
Effect of valsartan on the incidence of diabetes and cardiovascular events.
Topics: Angiotensin II Type 1 Receptor Blockers; Blood Glucose; Blood Pressure; Body Weight; Cardiovascular Diseases; Cyclohexanes; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Therapy, Combination; Exercise; Female; Follow-Up Studies; Glucose Intolerance; Humans; Hypoglycemic Agents; Incidence; Male; Middle Aged; Nateglinide; Phenylalanine; Proportional Hazards Models; Risk Factors; Tetrazoles; Valine; Valsartan | 2010 |
Postprandial endothelial dysfunction in subjects with new-onset type 2 diabetes: an acarbose and nateglinide comparative study.
Topics: Acarbose; Aged; Blood Glucose; Brachial Artery; Cyclohexanes; Diabetes Mellitus, Type 2; Endothelium, Vascular; Female; Food; Humans; Hypoglycemic Agents; Insulin; Laser-Doppler Flowmetry; Male; Middle Aged; Nateglinide; Phenylalanine; Vasodilation | 2010 |
[NAVIGATOR: A trial of prevention of cardiovascular complications and type 2 diabetes with valsartan and/or nateglinide].
Topics: Angiotensin II Type 1 Receptor Blockers; Belgium; Cardiovascular Diseases; Cyclohexanes; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Therapy, Combination; Female; Follow-Up Studies; Humans; Hypoglycemic Agents; Male; Middle Aged; Nateglinide; Phenylalanine; Renin-Angiotensin System; Tetrazoles; Treatment Outcome; Valine; Valsartan | 2010 |
Additive hypoglycaemic effect of nateglinide and exogenous glucagon-like peptide-1 in type 2 diabetes.
Topics: Aged; Blood Glucose; Cross-Over Studies; Cyclohexanes; Diabetes Mellitus, Type 2; Drug Synergism; Drug Therapy, Combination; Female; Glucagon-Like Peptide 1; Humans; Hypoglycemic Agents; Male; Nateglinide; Phenylalanine; Postprandial Period; Treatment Outcome | 2011 |
Nateglinide provides tighter glycaemic control than glyburide in patients with Type 2 diabetes with prevalent postprandial hyperglycaemia.
Topics: Adult; Aged; Aged, 80 and over; Cardiovascular Diseases; Cyclohexanes; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Double-Blind Method; Fasting; Female; Glyburide; Glycated Hemoglobin; Humans; Hyperglycemia; Middle Aged; Nateglinide; Phenylalanine; Postprandial Period | 2011 |
Nateglinide and acarbose for postprandial glucose control after optimizing fasting glucose with insulin glargine in patients with type 2 diabetes.
Topics: Acarbose; Adult; Aged; Aged, 80 and over; Blood Glucose; Cyclohexanes; Diabetes Mellitus, Type 2; Fasting; Female; Humans; Hypoglycemic Agents; Insulin; Insulin Glargine; Insulin, Long-Acting; Male; Middle Aged; Nateglinide; Phenylalanine; Postprandial Period; Treatment Outcome | 2011 |
Efficacy and safety of mitiglinide versus nateglinide in newly diagnose patients with type 2 diabetes mellitus: a randomized double blind trial.
Topics: Blood Glucose; Body Mass Index; Cyclohexanes; Diabetes Mellitus, Type 2; Double-Blind Method; Fasting; Female; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Isoindoles; Male; Middle Aged; Nateglinide; Phenylalanine; Postprandial Period; Treatment Outcome; Waist-Hip Ratio | 2012 |
Neuromuscular electrical stimulation increases muscle protein synthesis in elderly type 2 diabetic men.
Topics: Aged; Atrophy; Bed Rest; Biopsy, Needle; Carbon Isotopes; Diabetes Mellitus, Type 2; Electric Stimulation Therapy; Gene Expression Regulation; Humans; Immobilization; Kinetics; Male; Muscle Proteins; Myostatin; Neuromuscular Junction; Phenylalanine; Quadriceps Muscle; RNA, Messenger; Sarcopenia | 2012 |
Combination therapy with nateglinide and a thiazolidinedione improves glycemic control in type 2 diabetes.
Topics: Adult; Aged; Cyclohexanes; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Female; Glycated Hemoglobin; Humans; Hyperglycemia; Hypoglycemic Agents; Male; Middle Aged; Nateglinide; Phenylalanine; Thiazoles; Thiazolidinediones; Treatment Outcome | 2002 |
Efficacy and safety of nateglinide in type 2 diabetic patients with modest fasting hyperglycemia.
Topics: Adult; Blood Glucose; Cyclohexanes; Diabetes Mellitus, Type 2; Double-Blind Method; Fasting; Female; Glycated Hemoglobin; Humans; Hyperglycemia; Hypoglycemia; Hypoglycemic Agents; Incidence; Insulin; Insulin Secretion; Male; Nateglinide; Phenylalanine; Racial Groups; Treatment Outcome | 2002 |
Amino acid ingestion strongly enhances insulin secretion in patients with long-term type 2 diabetes.
Topics: Amino Acids; Blood Glucose; Diabetes Mellitus, Type 2; Dietary Carbohydrates; Humans; Insulin; Insulin Secretion; Leucine; Male; Middle Aged; Phenylalanine; Protein Hydrolysates | 2003 |
Pharmacokinetics of nateglinide in renally impaired diabetic patients.
Topics: Adult; Aged; Area Under Curve; Blood Glucose; Case-Control Studies; Cyclohexanes; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Female; Half-Life; Humans; Hypoglycemic Agents; Kidney Failure, Chronic; Male; Metabolic Clearance Rate; Middle Aged; Nateglinide; Phenylalanine; Renal Dialysis | 2003 |
Efficacy and safety of nateglinide in the treatment of type II diabetes mellitus.
Topics: Blood Glucose; Cyclohexanes; Diabetes Mellitus, Type 2; Female; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Male; Middle Aged; Nateglinide; Phenylalanine; Prospective Studies; Treatment Outcome | 2002 |
Evaluation of the effects of nateglinide on postprandial glycemia in patients with type 2 diabetes mellitus: a multicenter, multinational, non-randomized, non-controlled Latin American study.
Topics: Blood Glucose; Cyclohexanes; Diabetes Mellitus, Type 2; Female; Humans; Hyperglycemia; Hypoglycemic Agents; Latin America; Male; Middle Aged; Nateglinide; Phenylalanine; Postprandial Period; Treatment Outcome | 2003 |
Addition of nateglinide to rosiglitazone monotherapy suppresses mealtime hyperglycemia and improves overall glycemic control.
Topics: Blood Glucose; Cyclohexanes; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Eating; Fasting; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Insulin; Middle Aged; Nateglinide; Phenylalanine; Placebos; Rosiglitazone; Safety; Single-Blind Method; Thiazolidinediones; Time Factors | 2003 |
Efficacy and safety of combination therapy: repaglinide plus metformin versus nateglinide plus metformin.
Topics: Area Under Curve; Blood Glucose; Carbamates; Cyclohexanes; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Female; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Insulin; Male; Metformin; Middle Aged; Nateglinide; Phenylalanine; Piperidines; Postprandial Period; Safety | 2003 |
Pharmacokinetics of nateglinide and its metabolites in subjects with type 2 diabetes mellitus and renal failure.
Topics: Adult; Aged; Aged, 80 and over; Area Under Curve; Cyclohexanes; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Female; Humans; Hypoglycemic Agents; Male; Middle Aged; Nateglinide; Phenylalanine; Renal Insufficiency; Time Factors | 2003 |
Efficacy, tolerability and safety of nateglinide in combination with metformin. Results from a study under general practice conditions.
Topics: Adult; Aged; Aged, 80 and over; Blood Glucose; Blood Pressure; Body Weight; Cyclohexanes; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Family Practice; Female; Humans; Hypoglycemic Agents; Male; Metformin; Middle Aged; Nateglinide; Phenylalanine; Postprandial Period; Product Surveillance, Postmarketing | 2003 |
Effects of nateglinide on the secretion of glycated insulin and glucose tolerance in type 2 diabetes.
Topics: Blood Glucose; C-Peptide; Cross-Over Studies; Cyclohexanes; Diabetes Mellitus, Type 2; Female; Glucose Tolerance Test; Glycosylation; Humans; Hypoglycemic Agents; Insulin; Insulin Secretion; Islets of Langerhans; Male; Middle Aged; Nateglinide; Phenylalanine; Single-Blind Method | 2003 |
Targeting postprandial hyperglycemia: a comparative study of insulinotropic agents in type 2 diabetes.
Topics: Adult; Aged; Blood Glucose; C-Peptide; Cross-Over Studies; Cyclohexanes; Delayed-Action Preparations; Diabetes Mellitus, Type 2; Female; Glipizide; Humans; Hyperglycemia; Hypoglycemic Agents; Insulin; Male; Middle Aged; Nateglinide; Phenylalanine; Postprandial Period | 2003 |
A placebo-controlled crossover study comparing the effects of nateglinide and glibenclamide on postprandial hyperglycaemia and hyperinsulinaemia in patients with type 2 diabetes.
Topics: Aged; Blood Glucose; C-Peptide; Cross-Over Studies; Cyclohexanes; Diabetes Mellitus, Type 2; Double-Blind Method; Female; Glyburide; Humans; Hypoglycemic Agents; Insulin; Male; Middle Aged; Nateglinide; Phenylalanine; Postprandial Period | 2004 |
Evaluation of a new insulinotropic agent by using an innovative technology: efficacy and safety of nateglinide determined by continuous glucose monitoring.
Topics: Blood Glucose; Blood Glucose Self-Monitoring; Cyclohexanes; Diabetes Mellitus, Type 2; Female; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Male; Middle Aged; Nateglinide; Phenylalanine; Postprandial Period; Prospective Studies; Statistics, Nonparametric | 2004 |
Repaglinide versus nateglinide monotherapy: a randomized, multicenter study.
Topics: Biomarkers; Body Mass Index; Carbamates; Cyclohexanes; Diabetes Mellitus, Type 2; Diet, Diabetic; Exercise; Female; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Male; Middle Aged; Nateglinide; Phenylalanine; Piperidines; Time Factors | 2004 |
Efficacy and tolerability of initial combination therapy with nateglinide and metformin in treatment-naïve patients with type 2 diabetes.
Topics: Cyclohexanes; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Therapy, Combination; Female; Humans; Hypoglycemic Agents; Male; Metformin; Middle Aged; Nateglinide; Phenylalanine; Placebos; Treatment Outcome; United States | 2004 |
Nateglinide alone or with metformin safely improves glycaemia to target in patients up to an age of 84.
Topics: Adult; Aged; Aged, 80 and over; Blood Glucose; Cyclohexanes; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Female; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Male; Metformin; Middle Aged; Nateglinide; Phenylalanine; Postprandial Period; Prospective Studies; Regression Analysis | 2004 |
A single dose of nateglinide improves post-challenge glucose metabolism and endothelial dysfunction in Type 2 diabetic patients.
Topics: Administration, Oral; Blood Glucose; Cross-Over Studies; Cyclohexanes; Diabetes Mellitus, Type 2; Double-Blind Method; Endothelium; Female; Forearm; Glucose; Humans; Hypoglycemic Agents; Insulin; Male; Middle Aged; Nateglinide; Phenylalanine; Regional Blood Flow | 2004 |
Efficacy and safety of once daily gliclazide (20 mg/day) compared with nateglinide.
Topics: Adult; Cross-Over Studies; Cyclohexanes; Deoxyglucose; Diabetes Mellitus, Type 2; Gliclazide; Glycated Hemoglobin; Glycated Serum Albumin; Glycation End Products, Advanced; Humans; Hypoglycemic Agents; Lipoproteins, LDL; Malondialdehyde; Nateglinide; Phenylalanine; Prospective Studies; Serum Albumin; Thiobarbituric Acid Reactive Substances | 2004 |
Hypoglycemic potential of nateglinide versus glyburide in patients with type 2 diabetes mellitus.
Topics: Adult; Aged; Area Under Curve; Blood Glucose; Cyclohexanes; Diabetes Mellitus, Type 2; Double-Blind Method; Female; Glucose Clamp Technique; Glyburide; Humans; Hypoglycemic Agents; Insulin; Male; Middle Aged; Nateglinide; Phenylalanine | 2004 |
Effects of nateglinide on myocardial microvascular reactivity in Type 2 diabetes mellitus--a randomized study using positron emission tomography.
Topics: Aged; Blood Glucose; Blood Pressure; Coronary Circulation; Cyclohexanes; Diabetes Mellitus, Type 2; Female; Humans; Hypoglycemic Agents; Lipids; Male; Microcirculation; Middle Aged; Nateglinide; Phenylalanine; Positron-Emission Tomography; Treatment Outcome | 2005 |
Effects of nateglinide on the elevation of postprandial remnant-like particle triglyceride levels in Japanese patients with type 2 diabetes assessment by meal tolerance test.
Topics: Blood Glucose; Cholesterol; Cyclohexanes; Diabetes Mellitus, Type 2; Humans; Hyperglycemia; Hypoglycemic Agents; Insulin; Japan; Lipoproteins; Middle Aged; Nateglinide; Phenylalanine; Postprandial Period; Triglycerides | 2004 |
[Comparison of efficacy between nateglinide and repaglinide in treating type 2 diabetes: a randomized controlled double-blind clinical trial].
Topics: Adult; Blood Glucose; Carbamates; Cyclohexanes; Diabetes Mellitus, Type 2; Double-Blind Method; Female; Humans; Hypoglycemic Agents; Insulin; Insulin Secretion; Male; Middle Aged; Nateglinide; Phenylalanine; Piperidines | 2005 |
Beta-cell function in mild type 2 diabetic patients: effects of 6-month glucose lowering with nateglinide.
Topics: Aged; Blood Glucose; Cyclohexanes; Diabetes Mellitus, Type 2; Female; Humans; Hypoglycemic Agents; Insulin Resistance; Islets of Langerhans; Male; Middle Aged; Models, Biological; Nateglinide; Phenylalanine; Placebos; Severity of Illness Index | 2005 |
Acute nateglinide administration in subjects with type 2 diabetes: effects on postprandial metabolism, coagulation, and fibrinolysis.
Topics: Adult; Aged; Blood Coagulation; Cardiovascular Diseases; Cross-Over Studies; Cyclohexanes; Diabetes Mellitus, Type 2; Female; Fibrinolysis; Humans; Hypoglycemic Agents; Lipids; Male; Metabolism; Middle Aged; Nateglinide; Phenylalanine; Postprandial Period; Treatment Outcome | 2005 |
Co-ingestion of a protein hydrolysate and amino acid mixture with carbohydrate improves plasma glucose disposal in patients with type 2 diabetes.
Topics: Blood Glucose; Case-Control Studies; Diabetes Mellitus, Type 2; Dietary Carbohydrates; Drug Interactions; Humans; Insulin; Insulin Secretion; Leucine; Male; Middle Aged; Phenylalanine; Protein Hydrolysates | 2005 |
PRESERVE-beta: two-year efficacy and safety of initial combination therapy with nateglinide or glyburide plus metformin.
Topics: Body Mass Index; Cyclohexanes; Diabetes Mellitus, Type 2; Drug Administration Schedule; Drug Therapy, Combination; Female; Glyburide; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Male; Middle Aged; Nateglinide; Phenylalanine; Placebos | 2005 |
Beneficial effects of nateglinide on insulin resistance in type 2 diabetes.
Topics: Blood Glucose; Body Mass Index; Cyclohexanes; Diabetes Mellitus, Type 2; Glycated Hemoglobin; Humans; Hyperglycemia; Hypoglycemic Agents; Insulin; Insulin Resistance; Insulin Secretion; Middle Aged; Nateglinide; Phenylalanine; Postprandial Period | 2006 |
Improved prandial glucose control with lower risk of hypoglycemia with nateglinide than with glibenclamide in patients with maturity-onset diabetes of the young type 3.
Topics: Adult; Aged; Blood Glucose; C-Peptide; Cross-Over Studies; Cyclohexanes; Diabetes Mellitus, Type 2; Double-Blind Method; Exercise Test; Female; Glucagon; Glyburide; Humans; Hypoglycemia; Hypoglycemic Agents; Insulin; Male; Middle Aged; Nateglinide; Phenylalanine; Postprandial Period | 2006 |
Efficacy and adverse effects of nateglinide in early type 2 diabetes. Comparison with voglibose in a cross-over study.
Topics: Aged; alpha-Glucosidases; Appetite; Body Weight; Cross-Over Studies; Cyclohexanes; Diabetes Mellitus, Type 2; Drug-Related Side Effects and Adverse Reactions; Female; Follow-Up Studies; Gastrointestinal Tract; Glycated Hemoglobin; Humans; Hypoglycemia; Inositol; Lipids; Liver Function Tests; Male; Middle Aged; Nateglinide; Phenylalanine; Treatment Outcome | 2006 |
Postprandial interstitial insulin concentrations in type 2 diabetes relatives.
Topics: Adipose Tissue; Adult; Anthropometry; Biological Transport; Cyclohexanes; Diabetes Mellitus, Type 2; Double-Blind Method; Female; Humans; Hypoglycemic Agents; Insulin; Insulin Resistance; Insulin Secretion; Lipolysis; Male; Microdialysis; Middle Aged; Nateglinide; Phenylalanine; Postprandial Period; Regional Blood Flow | 2006 |
Comparison of nateglinide and gliclazide in combination with metformin, for treatment of patients with Type 2 diabetes mellitus inadequately controlled on maximum doses of metformin alone.
Topics: Adult; Aged; Aged, 80 and over; Blood Glucose; Cyclohexanes; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Therapy, Combination; Female; Gliclazide; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Insulin; Male; Metformin; Middle Aged; Nateglinide; Phenylalanine; Postprandial Period; Treatment Outcome | 2006 |
Nateglinide with glibenclamide examination using the respiratory quotient (RQ).
Topics: Aged; Blood Glucose; Body Weight; Cyclohexanes; Diabetes Mellitus, Type 2; Female; Glyburide; Humans; Hypoglycemic Agents; Insulin Resistance; Lipid Metabolism; Lipids; Male; Middle Aged; Nateglinide; Phenylalanine; Weight Gain | 2006 |
Insulin glargine in combination with nateglinide in people with Type 2 diabetes: a randomized placebo-controlled trial.
Topics: Adult; Aged; Aged, 80 and over; Analysis of Variance; Blood Glucose; Blood Glucose Self-Monitoring; Cyclohexanes; Diabetes Mellitus, Type 2; Drug Administration Schedule; Drug Therapy, Combination; Female; Humans; Hypoglycemic Agents; Insulin; Insulin Glargine; Insulin, Long-Acting; Male; Metformin; Middle Aged; Nateglinide; Phenylalanine; Time Factors | 2007 |
Beneficial metabolic effects of nateglinide versus acarbose in patients with newly-diagnosed type 2 diabetes.
Topics: Acarbose; Arginine; Blood Glucose; Cross-Over Studies; Cyclohexanes; Diabetes Mellitus, Type 2; Female; Humans; Hypoglycemic Agents; Insulin; Lipids; Male; Middle Aged; Nateglinide; Phenylalanine; Prospective Studies | 2007 |
Nateglinide or gliclazide in combination with metformin for treatment of patients with type 2 diabetes mellitus inadequately controlled on maximum doses of metformin alone: 1-year trial results.
Topics: Aged; Cyclohexanes; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Therapy, Combination; Female; Gliclazide; Glycated Hemoglobin; Humans; Hypoglycemia; Hypoglycemic Agents; Male; Metformin; Middle Aged; Nateglinide; Phenylalanine; Safety; Time Factors | 2007 |
Improvement of insulin sensitivity and beta-cell function by nateglinide and repaglinide in type 2 diabetic patients - a randomized controlled double-blind and double-dummy multicentre clinical trial.
Topics: Adult; Age of Onset; Aged; Area Under Curve; Asian People; Blood Glucose; Carbamates; China; Cyclohexanes; Diabetes Mellitus, Type 2; Double-Blind Method; Humans; Insulin; Insulin Secretion; Insulin-Secreting Cells; Middle Aged; Nateglinide; Phenylalanine; Piperidines | 2007 |
Nateglinide reduces carotid intima-media thickening in type 2 diabetic patients under good glycemic control.
Topics: Aged; Blood Glucose; Carotid Arteries; Coronary Artery Disease; Cyclohexanes; Diabetes Mellitus, Type 2; Female; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Male; Middle Aged; Nateglinide; Phenylalanine; Tunica Intima; Tunica Media | 2007 |
Nateglinide, alone or in combination with metformin, is effective and well tolerated in treatment-naïve elderly patients with type 2 diabetes.
Topics: Aged; Aged, 80 and over; Blood Glucose; Body Mass Index; Cyclohexanes; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Administration Schedule; Drug Combinations; Female; Glyburide; Glycated Hemoglobin; Humans; Hypoglycemia; Hypoglycemic Agents; Male; Metformin; Middle Aged; Nateglinide; Phenylalanine; Treatment Outcome | 2008 |
Effects of nateglinide and glibenclamide on prothrombotic factors in naïve type 2 diabetic patients treated with metformin: a 1-year, double-blind, randomized clinical trial.
Topics: Adult; Cyclohexanes; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Therapy, Combination; Female; Glyburide; Humans; Hypoglycemic Agents; Male; Metformin; Middle Aged; Nateglinide; Phenylalanine; Plasminogen Activator Inhibitor 1; Tissue Plasminogen Activator | 2007 |
Effect of combination therapy of a rapid-acting insulin secretagogue (glinide) with premixed insulin in type 2 diabetes mellitus.
Topics: Aged; Blood Glucose; Cyclohexanes; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Female; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Insulin; Isoindoles; Japan; Male; Middle Aged; Multicenter Studies as Topic; Nateglinide; Phenylalanine; Treatment Outcome | 2007 |
Improvement of glycaemic control by nateglinide decreases systolic blood pressure in drug-naive patients with type 2 diabetes.
Topics: Adult; Aged; Area Under Curve; Blood Glucose; Blood Pressure; Cholesterol; Cyclohexanes; Diabetes Mellitus, Type 2; Double-Blind Method; Female; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Male; Middle Aged; Nateglinide; Phenylalanine; Triglycerides | 2008 |
[Clinical evaluation of efficacy and safety of nateglinide in the treatment of type 2 diabetes].
Topics: Blood Glucose; Cyclohexanes; Diabetes Mellitus, Type 2; Drug Administration Schedule; Female; Humans; Hypoglycemic Agents; Male; Middle Aged; Nateglinide; Phenylalanine; Treatment Outcome | 2008 |
Effects of metformin treatment on whole-body and splanchnic amino acid turnover in mild type 2 diabetes.
Topics: Amino Acids; Blood Glucose; Carbon Radioisotopes; Diabetes Mellitus, Type 2; Double-Blind Method; Fatty Acids, Nonesterified; Female; Food; Glucagon; Humans; Kinetics; Male; Metformin; Middle Aged; Phenylalanine; Placebos; Proteins; Tritium | 1994 |
Modulation of insulin secretion in non-insulin-dependent diabetes mellitus by two novel oral hypoglycaemic agents, NN623 and A4166.
Topics: Administration, Oral; Biological Availability; Blood Glucose; Carbamates; Cyclohexanes; Diabetes Mellitus, Type 2; Glyburide; Humans; Hypoglycemic Agents; Insulin; Insulin Secretion; Intestinal Absorption; Molecular Structure; Nateglinide; Phenylalanine; Piperidines; Reference Values; Stereoisomerism | 1996 |
Synergistic effects of nateglinide and meal administration on insulin secretion in patients with type 2 diabetes mellitus.
Topics: Adult; Aged; Area Under Curve; Blood Glucose; Cyclohexanes; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Double-Blind Method; Eating; Fasting; Female; Humans; Hypoglycemic Agents; Insulin; Male; Middle Aged; Nateglinide; Phenylalanine; Time Factors | 2000 |
Effects of the new oral hypoglycaemic agent nateglinide on insulin secretion in Type 2 diabetes mellitus.
Topics: Adult; Aged; Blood Glucose; C-Peptide; Cyclohexanes; Diabetes Mellitus, Type 2; Double-Blind Method; Humans; Hypoglycemic Agents; Insulin; Insulin Secretion; Kinetics; Male; Middle Aged; Nateglinide; Phenylalanine; Placebos; Proinsulin | 2000 |
Rapid and short-acting mealtime insulin secretion with nateglinide controls both prandial and mean glycemia.
Topics: Adult; Aged; Area Under Curve; Blood Glucose; Cyclohexanes; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Administration Schedule; Eating; Female; Humans; Hypoglycemic Agents; Insulin; Insulin Secretion; Male; Middle Aged; Nateglinide; Phenylalanine; Placebos; Safety | 2000 |
Improved control of mealtime glucose excursions with coadministration of nateglinide and metformin.
Topics: Adult; Aged; Blood Glucose; Cyclohexanes; Diabetes Mellitus, Type 2; Drug Administration Schedule; Drug Therapy, Combination; Eating; Female; Glyburide; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Insulin; Male; Metformin; Middle Aged; Nateglinide; Phenylalanine; Postprandial Period | 2000 |
Mealtime glucose regulation by nateglinide in type-2 diabetes mellitus.
Topics: Blood Glucose; Cross-Over Studies; Cyclohexanes; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administration Schedule; Female; Humans; Hypoglycemic Agents; Insulin; Male; Middle Aged; Nateglinide; Phenylalanine; Placebos | 2000 |
Nateglinide alone and in combination with metformin improves glycemic control by reducing mealtime glucose levels in type 2 diabetes.
Topics: Aged; Blood Glucose; Cyclohexanes; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Therapy, Combination; Eating; Ethnicity; Fasting; Female; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Male; Metformin; Middle Aged; Nateglinide; Phenylalanine; Prospective Studies; United States | 2000 |
Impairment of early insulin response after glucose load, rather than insulin resistance, is responsible for postprandial hyperglycemia seen in obese type 2 diabetes: assessment using nateglinide, a new insulin secretagogue.
Topics: Adult; Cyclohexanes; Diabetes Mellitus, Type 2; Female; Glucose; Humans; Hyperglycemia; Hypoglycemic Agents; Insulin; Insulin Resistance; Insulin Secretion; Male; Middle Aged; Nateglinide; Obesity; Phenylalanine; Postprandial Period | 2000 |
Importance of early insulin secretion: comparison of nateglinide and glyburide in previously diet-treated patients with type 2 diabetes.
Topics: Aged; Area Under Curve; Blood Glucose; C-Peptide; Cyclohexanes; Diabetes Mellitus, Type 2; Diet, Diabetic; Double-Blind Method; Fasting; Female; Glyburide; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Insulin; Insulin Secretion; Male; Middle Aged; Nateglinide; Phenylalanine; Placebos; Postprandial Period; Proinsulin; Single-Blind Method; Time Factors | 2001 |
Randomized dose ranging study of the reduction of fasting and postprandial glucose in type 2 diabetes by nateglinide (A-4166).
Topics: Blood Glucose; Cross-Over Studies; Cyclohexanes; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Double-Blind Method; Fasting; Female; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Insulin; Male; Middle Aged; Nateglinide; Phenylalanine; Postprandial Period | 2001 |
Nuclear factor-kappaB suppressive and inhibitor-kappaB stimulatory effects of troglitazone in obese patients with type 2 diabetes: evidence of an antiinflammatory action?
Topics: Adult; Anti-Inflammatory Agents; Blood Glucose; C-Reactive Protein; Chemokine CCL2; Cholesterol; Chromans; Diabetes Mellitus; Diabetes Mellitus, Type 2; Female; Humans; I-kappa B Proteins; Insulin; Intercellular Adhesion Molecule-1; Leukocytes, Mononuclear; Linoleic Acid; Linoleic Acids; Linoleic Acids, Conjugated; Male; Middle Aged; NADPH Oxidases; Neutrophils; NF-kappa B; Obesity; Phenylalanine; Phosphoproteins; Plasminogen Activator Inhibitor 1; Reactive Oxygen Species; Thiazoles; Thiazolidinediones; Triglycerides; Troglitazone; Tyrosine | 2001 |
Effects of timing of administration and meal composition on the pharmacokinetic and pharmacodynamic characteristics of the short-acting oral hypoglycemic agent nateglinide in healthy subjects.
Topics: Area Under Curve; C-Peptide; Cross-Over Studies; Cyclohexanes; Diabetes Mellitus, Type 2; Dietary Carbohydrates; Dietary Fats; Dietary Proteins; Double-Blind Method; Humans; Hypoglycemic Agents; Nateglinide; Phenylalanine; Time Factors | 2001 |
Importance of early phase insulin secretion to intravenous glucose tolerance in subjects with type 2 diabetes mellitus.
Topics: Aged; Cross-Over Studies; Cyclohexanes; Diabetes Mellitus, Type 2; Female; Glucose; Glucose Tolerance Test; Glyburide; Humans; Hypoglycemic Agents; Insulin; Insulin Secretion; Male; Middle Aged; Nateglinide; Phenylalanine; Reproducibility of Results; Sodium Chloride; Time Factors | 2001 |
Nateglinide improves glycaemic control when added to metformin monotherapy: results of a randomized trial with type 2 diabetes patients.
Topics: Aged; Blood Glucose; Body Mass Index; Body Weight; Cholesterol; Cyclohexanes; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Therapy, Combination; Female; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Male; Metformin; Middle Aged; Nateglinide; Phenylalanine; Placebos; Racial Groups; Safety; Triglycerides | 2002 |
96 other study(ies) available for phenylalanine and Diabetes Mellitus, Adult-Onset
| Article | Year |
|---|---|
An exercise-inducible metabolite that suppresses feeding and obesity.
Topics: Adiposity; Animals; Body Weight; Diabetes Mellitus, Type 2; Disease Models, Animal; Eating; Energy Metabolism; Feeding Behavior; Glucose; Lactic Acid; Mice; Obesity; Phenylalanine; Physical Conditioning, Animal | 2022 |
Phenylalanine impairs insulin signaling and inhibits glucose uptake through modification of IRβ.
Topics: Animals; Diabetes Mellitus, Type 2; Glucose; Humans; Insulin; Insulin Resistance; Mice; Phenylalanine; Sirtuin 1 | 2022 |
NMR-Based Metabolomic Analysis for the Effects of Trimethylamine N-Oxide Treatment on C2C12 Myoblasts under Oxidative Stress.
Topics: Alanine; Catalase; Diabetes Mellitus, Type 2; Glycine; Histidine; Humans; Hydrogen Peroxide; Isoleucine; Leucine; Magnetic Resonance Spectroscopy; Malondialdehyde; Methylamines; Myoblasts; Oxidative Stress; Phenylalanine; Phosphorylcholine; Superoxide Dismutase; Threonine; Valine | 2022 |
Metabolomics analysis of stool in rats with type 2 diabetes mellitus after single-anastomosis duodenal-ileal bypass with sleeve gastrectomy.
Topics: Alanine; Amino Acids, Aromatic; Amino Acids, Branched-Chain; Anastomosis, Surgical; Animals; Bile Acids and Salts; Blood Glucose; Diabetes Mellitus, Type 2; Gastrectomy; Glutamates; Glycated Hemoglobin; Ileum; Isobutyrates; Lithocholic Acid; Obesity, Morbid; Phenylalanine; Phospholipids; Proline; Rats; Streptozocin; Valine | 2022 |
Isotope-edited vibrational circular dichroism study reveals a flexible N-terminal structure of islet amyloid peptide (NFGAIL) in amyloid fibril form: A site-specific local structural analysis.
Topics: Amyloid; Diabetes Mellitus, Type 2; Glycine; Humans; Isotopes; Peptides; Phenylalanine | 2022 |
Metabolic Reprogramming in SARS-CoV-2 Infection Impacts the Outcome of COVID-19 Patients.
Topics: Amino Acids; COVID-19; Cross-Sectional Studies; Diabetes Mellitus, Type 2; Humans; Phenylalanine; SARS-CoV-2 | 2022 |
Circulating metabolites and the risk of type 2 diabetes: a prospective study of 11,896 young adults from four Finnish cohorts.
Topics: Adult; Biomarkers; Blood Glucose; Cholesterol; Diabetes Mellitus, Type 2; Fatty Acids; Female; Finland; Humans; Incidence; Insulin; Insulin Resistance; Male; Middle Aged; Phenylalanine; Risk; Young Adult | 2019 |
Plasma phenylalanine and tyrosine and their interactions with diabetic nephropathy for risk of diabetic retinopathy in type 2 diabetes.
Topics: Diabetes Mellitus, Type 2; Diabetic Nephropathies; Diabetic Retinopathy; Humans; Phenylalanine; Tyrosine | 2020 |
Accelerated whole-body protein catabolism in subjects with type 2 Diabetes Mellitus and albuminuria.
Topics: Adult; Albuminuria; Diabetes Mellitus, Type 2; Female; Humans; Male; Middle Aged; Phenylalanine; Protein Biosynthesis; Proteolysis | 2020 |
Maternal BMI and Glycemia Impact the Fetal Metabolome.
Topics: 3-Hydroxybutyric Acid; Adiposity; Adult; Amino Acids, Branched-Chain; Birth Weight; Blood Glucose; Body Mass Index; Cohort Studies; Diabetes Mellitus, Type 2; Ethnicity; Female; Fetal Blood; Fetus; Glucose Tolerance Test; Humans; Infant, Newborn; Insulin Resistance; Linear Models; Male; Meta-Analysis as Topic; Metabolome; Metabolomics; Obesity; Phenylalanine; Pregnancy; Prenatal Exposure Delayed Effects; Triglycerides; Young Adult | 2017 |
Metabolomics insights into early type 2 diabetes pathogenesis and detection in individuals with normal fasting glucose.
Topics: Adult; Aged; Area Under Curve; Blood Glucose; Computational Biology; Diabetes Mellitus, Type 2; Female; Glycated Hemoglobin; Glycine; Humans; Incidence; Male; Mendelian Randomization Analysis; Metabolomics; Middle Aged; Phenylalanine; Prospective Studies; Risk Factors; ROC Curve; Tandem Mass Spectrometry; Taurine | 2018 |
Nine Amino Acids Are Associated With Decreased Insulin Secretion and Elevated Glucose Levels in a 7.4-Year Follow-up Study of 5,181 Finnish Men.
Topics: Aged; Alanine; Amino Acids; Aspartic Acid; Blood Glucose; Diabetes Mellitus, Type 2; Finland; Follow-Up Studies; Glutamic Acid; Humans; Insulin Resistance; Insulin Secretion; Isoleucine; Leucine; Male; Metabolomics; Middle Aged; Phenylalanine; Risk Factors; Tryptophan; Tyrosine; Valine | 2019 |
Design, synthesis, biological evaluation, and docking studies of (s)-phenylalanine derivatives with a 2-cyanopyrrolidine moiety as potent dipeptidyl peptidase 4 inhibitors.
Topics: Diabetes Mellitus, Type 2; Dipeptidyl Peptidase 4; Dipeptidyl-Peptidase IV Inhibitors; Drug Design; Humans; Molecular Docking Simulation; Phenylalanine; Pyrrolidines | 2013 |
Quantitative analytical method for determining the levels of gastric inhibitory polypeptides GIP1-42 and GIP3-42 in human plasma using LC-MS/MS/MS.
Topics: Amino Acid Sequence; Chromatography, Liquid; Diabetes Mellitus, Type 2; Gastric Inhibitory Polypeptide; Humans; Limit of Detection; Metalloendopeptidases; Molecular Sequence Data; Peptide Fragments; Phenylalanine; Proteolysis; Solid Phase Extraction; Tandem Mass Spectrometry | 2013 |
Postprandial lipid profile in patients with type 2 diabetes.
Topics: Acarbose; Blood Glucose; Cyclohexanes; Diabetes Mellitus, Type 2; Fatty Acids, Nonesterified; Humans; Hyperlipidemias; Hypoglycemic Agents; Nateglinide; Phenylalanine; Postprandial Period | 2014 |
Role of diuretics, β blockers, and statins in increasing the risk of diabetes in patients with impaired glucose tolerance: reanalysis of data from the NAVIGATOR study.
Topics: Adrenergic beta-Antagonists; Aged; Calcium Channel Blockers; Cardiovascular Diseases; Cyclohexanes; Diabetes Mellitus, Type 2; Diuretics; Double-Blind Method; Female; Follow-Up Studies; Glucose Intolerance; Glucose Tolerance Test; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Incidence; Male; Middle Aged; Models, Statistical; Nateglinide; Phenylalanine; Risk Factors; Tetrazoles; Treatment Outcome; Valine; Valsartan | 2013 |
[Prandial glucose regulator and insulin secretagogue; glinide and its combination therapy].
Topics: Cyclohexanes; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Humans; Hyperglycemia; Hypoglycemic Agents; Isoindoles; Nateglinide; Phenylalanine | 2015 |
Branched-chain and aromatic amino acid profiles and diabetes risk in Chinese populations.
Topics: Adult; Aged; Amino Acids, Aromatic; Amino Acids, Branched-Chain; China; Chromatography, Liquid; Cross-Sectional Studies; Diabetes Mellitus, Type 2; Female; Humans; Isoleucine; Leucine; Longitudinal Studies; Male; Mass Spectrometry; Middle Aged; Phenylalanine; Risk Factors; Tyrosine; Valine; Young Adult | 2016 |
GPR142 Controls Tryptophan-Induced Insulin and Incretin Hormone Secretion to Improve Glucose Metabolism.
Topics: Animals; Blood Glucose; Diabetes Mellitus, Type 2; Glucose; Humans; Incretins; Insulin; Insulin Secretion; Insulin-Secreting Cells; Islets of Langerhans; Mice; Mice, Knockout; Phenylalanine; Receptors, G-Protein-Coupled; Tryptophan | 2016 |
Tryptophan Predicts the Risk for Future Type 2 Diabetes.
Topics: Adult; Aged; Biomarkers; Blood Glucose; Case-Control Studies; China; Diabetes Mellitus, Type 2; Fasting; Female; Humans; Insulin; Insulin Resistance; Isoleucine; Leucine; Longitudinal Studies; Male; Middle Aged; Phenylalanine; Predictive Value of Tests; Prognosis; Risk Factors; Tryptophan; Tyrosine; Valine | 2016 |
International Variation in Outcomes Among People with Cardiovascular Disease or Cardiovascular Risk Factors and Impaired Glucose Tolerance: Insights from the NAVIGATOR Trial.
Topics: Aged; Angiotensin II Type 1 Receptor Blockers; Asia; Australia; Cardiovascular Diseases; Cyclohexanes; Diabetes Mellitus, Type 2; Europe; Female; Glucose Intolerance; Humans; Hypoglycemic Agents; Incidence; Latin America; Male; Middle Aged; Multivariate Analysis; Myocardial Infarction; Nateglinide; New Zealand; North America; Outcome Assessment, Health Care; Phenylalanine; Proportional Hazards Models; Randomized Controlled Trials as Topic; Risk Factors; South Africa; Stroke; Valsartan | 2017 |
Biomedical Informatics Approaches to Identifying Drug-Drug Interactions: Application to Insulin Secretagogues.
Topics: Area Under Curve; Carbamates; Cyclohexanes; Databases, Factual; Diabetes Mellitus, Type 2; Drug Interactions; Glipizide; Glyburide; Humans; Hypoglycemia; Hypoglycemic Agents; Medical Informatics; Nateglinide; Pharmacoepidemiology; Phenylalanine; Piperidines; Sulfonylurea Compounds | 2017 |
Genetically encoded photocross-linkers determine the biological binding site of exendin-4 peptide in the N-terminal domain of the intact human glucagon-like peptide-1 receptor (GLP-1R).
Topics: Azides; Binding Sites; Cyclic AMP; Diabetes Mellitus, Type 2; Exenatide; Glucagon-Like Peptide-1 Receptor; HEK293 Cells; Humans; Ligands; Molecular Dynamics Simulation; Molecular Structure; Mutagenesis; Mutation; Peptides; Phenylalanine; Protein Domains; Protein Multimerization; Structure-Activity Relationship; Ultraviolet Rays; Venoms | 2017 |
Pharmacokinetics of nateglinide enantiomers and their metabolites in Goto-Kakizaki rats, a model for type 2 diabetes mellitus.
Topics: Animals; Cyclohexanes; Diabetes Mellitus, Type 2; Disease Models, Animal; Hypoglycemic Agents; Male; Nateglinide; Phenylalanine; Rats; Rats, Wistar; Stereoisomerism | 2010 |
Hypoglycaemia with oral antidiabetic drugs: results from prescription-event monitoring cohorts of rosiglitazone, pioglitazone, nateglinide and repaglinide.
Topics: Administration, Oral; Adult; Adverse Drug Reaction Reporting Systems; Carbamates; Cohort Studies; Cyclohexanes; Diabetes Mellitus, Type 2; Drug Monitoring; Drug Prescriptions; Female; Humans; Hypoglycemia; Hypoglycemic Agents; Incidence; Male; Middle Aged; Nateglinide; Phenylalanine; Pioglitazone; Piperidines; Rosiglitazone; Sex Factors; Thiazolidinediones | 2009 |
Panel discussion on achieving glycemic control.
Topics: Blood Glucose; Cyclohexanes; Diabetes Mellitus, Type 2; Glycated Hemoglobin; Humans; Hyperglycemia; Hypoglycemic Agents; Metformin; Nateglinide; Phenylalanine; Sulfonylurea Compounds | 2001 |
Diabetes under control: Understanding oral antidiabetic agents.
Topics: Administration, Oral; Biguanides; Carbamates; Cyclohexanes; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Drug Combinations; Drug Therapy, Combination; Glycoside Hydrolase Inhibitors; Humans; Hypoglycemic Agents; Nateglinide; Phenylalanine; Piperidines; Sulfonylurea Compounds | 2010 |
Elucidating the pathways of degradation of denagliptin.
Topics: Amidines; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Drug Stability; Enzyme Inhibitors; Excipients; Hot Temperature; Humans; Magnetic Resonance Spectroscopy; Models, Molecular; Phenylalanine; Pyrrolidines | 2010 |
Navigating the choices for diabetes prevention.
Topics: Angiotensin II Type 1 Receptor Blockers; Blood Glucose; Cardiovascular Diseases; Cyclohexanes; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Glucose Intolerance; Humans; Hypoglycemic Agents; Nateglinide; Phenylalanine; Tetrazoles; Valine; Valsartan | 2010 |
The role of aromatic side-chains in amyloid growth and membrane interaction of the islet amyloid polypeptide fragment LANFLVH.
Topics: Alanine; Amino Acid Sequence; Amino Acids, Aromatic; Calorimetry, Differential Scanning; Cell Membrane; Diabetes Mellitus, Type 2; Humans; Hydrophobic and Hydrophilic Interactions; Islet Amyloid Polypeptide; Leucine; Lipid Bilayers; Microscopy, Atomic Force; Molecular Dynamics Simulation; Molecular Sequence Data; Peptide Fragments; Phenylalanine; Temperature | 2011 |
Effect of fluvastatin, lovastatin, nifedipine and verapamil on the systemic exposure of nateglinide in rabbits.
Topics: Animals; Area Under Curve; Aryl Hydrocarbon Hydroxylases; Calcium Channel Blockers; Cyclohexanes; Cytochrome P-450 CYP2C9; Cytochrome P450 Family 2; Diabetes Mellitus, Type 2; Drug Interactions; Fatty Acids, Monounsaturated; Fluvastatin; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypoglycemic Agents; Indoles; Lovastatin; Male; Nateglinide; Nifedipine; Phenylalanine; Rabbits; Steroid 21-Hydroxylase; Verapamil | 2010 |
Metabolomics identifies novel Hnf1alpha-dependent physiological pathways in vivo.
Topics: Adrenal Glands; Amino Acid Transport Systems; Animals; Diabetes Mellitus, Type 2; Hepatocyte Nuclear Factor 1-alpha; Indoles; Kidney; Liver; Male; Metabolomics; Mice; Mice, Knockout; Mutation; Phenylalanine; Tryptophan | 2010 |
Hypersensitivity to repaglinide.
Topics: Carbamates; Cyclohexanes; Diabetes Mellitus, Type 2; Drug Hypersensitivity; Erythema; Exanthema; Humans; Hypoglycemic Agents; Male; Middle Aged; Nateglinide; Patch Tests; Phenylalanine; Piperidines | 2011 |
Pharmacogenomic analysis of ATP-sensitive potassium channels coexpressing the common type 2 diabetes risk variants E23K and S1369A.
Topics: ATP-Binding Cassette Transporters; Chlorpropamide; Cyclohexanes; Diabetes Mellitus, Type 2; Gene Expression Regulation; Gliclazide; Glyburide; Haplotypes; Homozygote; Humans; Isoindoles; Nateglinide; Patch-Clamp Techniques; Phenylalanine; Polymorphism, Single Nucleotide; Potassium Channels, Inwardly Rectifying; Receptors, Drug; Structure-Activity Relationship; Sulfonylurea Compounds; Sulfonylurea Receptors; Tolbutamide | 2012 |
Discovery and characterization of an inhibitor of glucosylceramide synthase.
Topics: Adipose Tissue, White; Animals; Diabetes Mellitus, Type 2; Enzyme Inhibitors; Female; Gangliosides; Glucose Tolerance Test; Glucosyltransferases; Humans; Liver; Magnetic Resonance Spectroscopy; Mass Spectrometry; Mice; Mice, Inbred C57BL; Mice, Nude; Phenylalanine; Rats; Rats, Sprague-Dawley; Rats, Zucker; Structure-Activity Relationship; Triglycerides | 2012 |
[Glinides].
Topics: Benzamides; Cyclohexanes; Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Nateglinide; Phenylalanine | 2012 |
Discovery and optimization of a novel series of GPR142 agonists for the treatment of type 2 diabetes mellitus.
Topics: Animals; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Drug Discovery; Humans; Hypoglycemic Agents; Microsomes, Liver; Molecular Structure; Phenylalanine; Rats; Receptors, G-Protein-Coupled; Structure-Activity Relationship | 2012 |
Phenylalanine derivatives as GPR142 agonists for the treatment of type II diabetes.
Topics: Animals; Blood Glucose; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Drug Stability; Glucose Tolerance Test; HEK293 Cells; Humans; Hypoglycemic Agents; Insulin; Insulin Secretion; Male; Mice; Mice, Inbred Strains; Microsomes; Phenylalanine; Rats; Receptors, G-Protein-Coupled; Structure-Activity Relationship | 2012 |
Evaluating insulin secretagogues in a humanized mouse model with functional human islets.
Topics: Animals; Blood Glucose; Cyclohexanes; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Exenatide; Glucagon-Like Peptide 1; Glucose Tolerance Test; Glyburide; Humans; Incretins; Insulin; Insulin Secretion; Islets of Langerhans; Islets of Langerhans Transplantation; Male; Mice; Mice, Nude; Nateglinide; Peptides; Phenylalanine; Pyrazines; Sitagliptin Phosphate; Specific Pathogen-Free Organisms; Triazoles; Venoms | 2013 |
Identification of serum metabolites associated with risk of type 2 diabetes using a targeted metabolomic approach.
Topics: Adult; Biomarkers; Diabetes Mellitus, Type 2; Female; Glycine; Hexoses; Humans; Insulin; Insulin Resistance; Insulin Secretion; Male; Metabolomics; Middle Aged; Phenylalanine; Phosphatidylcholines; Risk; Serum; Sphingomyelins | 2013 |
A highly selective and potent PTP-MEG2 inhibitor with therapeutic potential for type 2 diabetes.
Topics: Animals; Diabetes Mellitus, Type 2; Disease Models, Animal; Mice; Mice, Inbred C57BL; Mice, Obese; Models, Molecular; Molecular Structure; Phenylalanine; Protein Tyrosine Phosphatases, Non-Receptor | 2012 |
Role of aromatic interactions in amyloid formation by islet amyloid polypeptide.
Topics: Amino Acid Sequence; Amino Acid Substitution; Diabetes Mellitus, Type 2; Humans; Islet Amyloid Polypeptide; Kinetics; Leucine; Models, Molecular; Molecular Sequence Data; Phenylalanine; Propanols; Tyrosine | 2013 |
Nateglinide in combination with metformin in Chinese patients with type 2 diabetes mellitus: a post-marketing surveillance study.
Topics: Aged; Body Weight; Cyclohexanes; Diabetes Mellitus, Type 2; Female; Humans; Hypoglycemic Agents; Male; Metformin; Middle Aged; Nateglinide; Phenylalanine; Product Surveillance, Postmarketing; Prospective Studies | 2013 |
[Dangerous postprandial glucose peaks. Risk for heart and blood vessels].
Topics: Cyclohexanes; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Drug Therapy, Combination; Humans; Hyperglycemia; Hypoglycemic Agents; Insulin Resistance; Metformin; Nateglinide; Phenylalanine; Postprandial Period | 2002 |
Synthesis rate of muscle proteins, muscle functions, and amino acid kinetics in type 2 diabetes.
Topics: Amino Acids; Blood Glucose; Carbon Isotopes; Diabetes Mellitus, Type 2; Energy Intake; Humans; Hypoglycemic Agents; Insulin; Kinetics; Leucine; Middle Aged; Muscle Fatigue; Muscle Proteins; Muscle, Skeletal; Phenylalanine; Reference Values | 2002 |
Decreased blood glucose excursion by nateglinide ameliorated neuropathic changes in Goto-Kakizaki rats, an animal model of non-obese type 2 diabetes.
Topics: Animals; Area Under Curve; Blood Glucose; Cyclohexanes; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Diabetic Neuropathies; Glyburide; Glycated Hemoglobin; Hypoglycemic Agents; Insulin; Nateglinide; Phenylalanine; Postprandial Period; Rats; Rats, Inbred Strains; Rats, Wistar; Sciatic Nerve; Time Factors | 2002 |
[Glinides and glitazones in diabetes treatment. Are they really effective?].
Topics: Carbamates; Cyclohexanes; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Humans; Hypoglycemic Agents; Insulin; Nateglinide; Phenylalanine; Pioglitazone; Piperidines; Rosiglitazone; Thiazoles; Thiazolidinediones; Treatment Outcome | 2002 |
Health and economic effects of adding nateglinide to metformin to achieve dual control of glycosylated hemoglobin and postprandial glucose levels in a model of type 2 diabetes mellitus.
Topics: Adult; Aged; Aged, 80 and over; Blood Glucose; Cohort Studies; Costs and Cost Analysis; Cyclohexanes; Diabetes Mellitus, Type 2; Drug Synergism; Drug Therapy, Combination; Female; Glycated Hemoglobin; Health Care Costs; Humans; Hypoglycemic Agents; Male; Metformin; Middle Aged; Models, Economic; Nateglinide; Phenylalanine; Postprandial Period | 2002 |
Hypoglycemia due to nateglinide administration in diabetic patient with chronic renal failure.
Topics: Blood Glucose; Cyclohexanes; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Female; Humans; Hypoglycemia; Hypoglycemic Agents; Kidney Failure, Chronic; Middle Aged; Nateglinide; Phenylalanine | 2003 |
Should diabetic patients treated long-term with sulfonylureas be switched to nateglinide?
Topics: Adult; Blood Glucose; Cyclohexanes; Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Male; Nateglinide; Phenylalanine; Sulfonylurea Compounds; Time | 2003 |
[Fasting hyperglycemia and postprandial glucose peaks. Diabetes therapy mustact on 2 sides].
Topics: Blood Glucose; Cyclohexanes; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Fasting; Humans; Hypoglycemic Agents; Metformin; Nateglinide; Phenylalanine; Postprandial Period | 2003 |
Glimepiride and serum adiponectin level in type 2 diabetic subjects: response to Nagasaka et al.
Topics: Adiponectin; Blood Glucose; Carbamates; Cyclohexanes; Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Intercellular Signaling Peptides and Proteins; Nateglinide; Phenylalanine; Piperidines; Proteins; Sulfonylurea Compounds | 2003 |
Comparison of repaglinide and nateglinide in combination with metformin: response to Raskin et al.
Topics: Carbamates; Cyclohexanes; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Metformin; Nateglinide; Phenylalanine; Piperidines | 2003 |
Metabolic stability, receptor binding, cAMP generation, insulin secretion and antihyperglycaemic activity of novel N-terminal Glu9-substituted analogues of glucagon-like peptide-1.
Topics: Adenosine Deaminase; Amino Acid Substitution; Animals; Binding, Competitive; Blood Glucose; Cell Line, Tumor; Cricetinae; Cyclic AMP; Diabetes Mellitus, Type 2; Dipeptidyl Peptidase 4; Fibroblasts; Glucagon; Glucagon-Like Peptide 1; Glucagon-Like Peptide-1 Receptor; Glucose; Glutamine; Glycoproteins; Humans; Hypoglycemic Agents; Insulin; Insulin Secretion; Islets of Langerhans; Mice; Mice, Obese; Peptide Fragments; Phenylalanine; Proline; Protein Precursors; Rats; Receptors, Glucagon; Spectrometry, Mass, Electrospray Ionization; Transformation, Genetic; Tyrosine | 2003 |
Comparison of voglibose and nateglinide for their acute effects on insulin secretion and free fatty acid levels in OLETF rat portal blood after sucrose loading.
Topics: Animals; Area Under Curve; Blood Glucose; Cyclohexanes; Diabetes Mellitus, Type 2; Disease Models, Animal; Enzyme Inhibitors; Fatty Acids, Nonesterified; Hypoglycemic Agents; Inositol; Insulin; Insulin Secretion; Male; Nateglinide; Phenylalanine; Portal Vein; Postprandial Period; Rats; Rats, Inbred OLETF; Secretory Rate; Sucrose | 2004 |
A new mouse model of type 2 diabetes, produced by N-ethyl-nitrosourea mutagenesis, is the result of a missense mutation in the glucokinase gene.
Topics: Adenine; Amino Acid Sequence; Amino Acid Substitution; Animals; Chromosome Mapping; Diabetes Mellitus, Type 2; Disease Models, Animal; Ethylnitrosourea; Glucokinase; Glucose; Glucose Intolerance; Heterozygote; Homozygote; Isoleucine; Male; Mice; Mice, Mutant Strains; Molecular Sequence Data; Mutagens; Mutation, Missense; Phenylalanine; Phosphorylation; Thymine | 2004 |
Restoration of early insulin secretion after a meal in type 2 diabetes: effects on lipid and glucose metabolism.
Topics: Blood Glucose; Cyclohexanes; Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Insulin; Insulin Secretion; Lipid Metabolism; Middle Aged; Nateglinide; Phenylalanine; Postprandial Period | 2004 |
Glutamine kinetics and protein turnover in end-stage renal disease.
Topics: Adult; Alanine; Arteries; Diabetes Mellitus, Type 2; Female; Glutamic Acid; Humans; Kidney Failure, Chronic; Male; Middle Aged; Models, Biological; Muscle, Skeletal; Phenylalanine; Proteins; Renal Dialysis; Veins | 2005 |
Comparing the long-term cost-effectiveness of repaglinide plus metformin versus nateglinide plus metformin in type 2 diabetes patients with inadequate glycaemic control: an application of the CORE Diabetes Model in type 2 diabetes.
Topics: Carbamates; Cohort Studies; Computer Simulation; Cost of Illness; Cost-Benefit Analysis; Cyclohexanes; Decision Support Systems, Clinical; Diabetes Complications; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Female; Glycated Hemoglobin; Health Care Costs; Humans; Male; Metformin; Middle Aged; Models, Econometric; Nateglinide; Outcome Assessment, Health Care; Phenylalanine; Piperidines; Quality-Adjusted Life Years | 2004 |
[A compensated type 2 diabetic patient? Fasting blood glucose can be deceptive].
Topics: Blood Glucose; Clinical Trials as Topic; Cyclohexanes; Diabetes Mellitus, Type 2; Fasting; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Nateglinide; Phenylalanine; Postprandial Period | 2004 |
Role of early insulin secretion in postglucose-loading hyperglycaemia and postfat-loading hyperlipidaemia: comparing nateglinide and glibenclamide for acute effects on insulin secretion in OLETF rats.
Topics: Adipose Tissue; Animals; Blood Glucose; Cyclohexanes; Diabetes Mellitus, Type 2; Dietary Fats; Gene Expression Regulation; Glyburide; Hyperglycemia; Hyperlipidemias; Hypoglycemic Agents; Insulin; Insulin Secretion; Lipoprotein Lipase; Male; Nateglinide; Phenylalanine; Postprandial Period; Rats; Rats, Inbred OLETF; Rats, Long-Evans; RNA, Messenger; Triglycerides | 2004 |
Inhibition of islet amyloid polypeptide fibril formation: a potential role for heteroaromatic interactions.
Topics: Amino Acid Substitution; Amyloid; Animals; Cell Line; Cell Survival; Diabetes Mellitus, Type 2; Flavonoids; Growth Inhibitors; Humans; Islet Amyloid Polypeptide; Islets of Langerhans; Mice; PC12 Cells; Peptide Fragments; Phenols; Phenolsulfonphthalein; Phenylalanine; Polyphenols; Protein Binding; Protein Interaction Mapping; Rats; Spectrometry, Fluorescence; Tyrosine | 2004 |
Treating type 2 diabetes. When diet and exercise aren't enough, a broad range of medications can help control our blood sugar.
Topics: Carbamates; Cyclohexanes; Diabetes Mellitus, Type 2; Drug Administration Schedule; Eating; Humans; Hypoglycemic Agents; Nateglinide; Phenylalanine; Piperidines | 2004 |
Effect of N-benzoyl-D-phenylalanine and metformin on carbohydrate metabolic enzymes in neonatal streptozotocin diabetic rats.
Topics: Animals; Animals, Newborn; Blood Glucose; Body Weight; Carbohydrate Metabolism; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Eating; Female; Gluconeogenesis; Glucosephosphate Dehydrogenase; Glycated Hemoglobin; Glycolysis; Hemoglobins; Hexokinase; Hypoglycemic Agents; Lipids; Liver; Liver Glycogen; Male; Metformin; Phenylalanine; Rats; Rats, Wistar | 2005 |
Indication for nateglinide in type 2 diabetes mellitus.
Topics: Age Factors; Aged; Cyclohexanes; Diabetes Mellitus, Type 2; Female; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Male; Middle Aged; Nateglinide; Obesity; Phenylalanine | 2005 |
Nateglinide, a non-sulfonylurea rapid insulin secretagogue, increases pancreatic islet blood flow in rats.
Topics: 3-O-Methylglucose; Administration, Oral; Anesthesia; Animals; Blood Glucose; Blood Pressure; Consciousness; Cyclohexanes; Diabetes Mellitus, Type 2; Enzyme Inhibitors; Gastrointestinal Tract; Glucose; Hypoglycemic Agents; Injections, Intravenous; Insulin; Insulin Secretion; Islets of Langerhans; Male; Nateglinide; Nitric Oxide Synthase; omega-N-Methylarginine; Phenylalanine; Rats; Rats, Inbred OLETF; Rats, Sprague-Dawley; Regional Blood Flow; Time Factors; Tolbutamide | 2005 |
Effect of N-benzoyl-d-phenylalanine on lipid profile in liver of neonatal streptozotocin diabetic rats.
Topics: Administration, Oral; Animals; Animals, Newborn; Blood Glucose; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; Glutathione; Hypoglycemic Agents; Insulin; Lipid Peroxidation; Lipids; Liver; Male; Metformin; Phenylalanine; Rats; Rats, Wistar; Streptozocin; Thiobarbituric Acid Reactive Substances | 2005 |
Accumulation of the hydroxyl free radical markers meta-, ortho-tyrosine and DOPA in cataractous lenses is accompanied by a lower protein and phenylalanine content of the water-soluble phase.
Topics: Aged; Cataract; Cross-Sectional Studies; Diabetes Mellitus, Type 2; Dihydroxyphenylalanine; Eye Proteins; Humans; Hydroxyl Radical; Lens, Crystalline; Middle Aged; Phenylalanine; Solubility; Tyrosine; Water | 2005 |
Favorable effects of early insulin secretion by nateglinide on postprandial hyperlipidemia in patients with type 2 diabetes.
Topics: Cyclohexanes; Diabetes Mellitus, Type 2; Humans; Hyperlipidemias; Hypoglycemic Agents; Insulin; Insulin Secretion; Nateglinide; Phenylalanine; Postprandial Period; Triglycerides | 2006 |
(2S,3S)-3-Amino-4-(3,3-difluoropyrrolidin-1-yl)-N,N-dimethyl-4-oxo-2-(4-[1,2,4]triazolo[1,5-a]-pyridin-6-ylphenyl)butanamide: a selective alpha-amino amide dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes.
Topics: Administration, Oral; Animals; Biological Availability; Calcium Channels, L-Type; Cell Line; Crystallography, X-Ray; Diabetes Mellitus, Type 2; Dipeptidyl Peptidase 4; Glucose Tolerance Test; Humans; Hypoglycemic Agents; In Vitro Techniques; Male; Mice; Mice, Inbred C57BL; Mice, Obese; Microsomes, Liver; Models, Molecular; Muscle Proteins; Muscle, Skeletal; NAV1.5 Voltage-Gated Sodium Channel; Phenylalanine; Protease Inhibitors; Rabbits; Sodium Channels; Stereoisomerism; Structure-Activity Relationship; Triazoles | 2006 |
Effects of mitiglinide on glucose-induced insulin release into the portal vein and fat-induced triglyceride elevation in prediabetic and diabetic OLETF rats.
Topics: Adipose Tissue; Animals; Blood Glucose; Cyclohexanes; Diabetes Mellitus, Type 2; Glucose Tolerance Test; Glyburide; Indoles; Insulin; Insulin Secretion; Isoindoles; Lipoprotein Lipase; Male; Nateglinide; Phenylalanine; Portal Vein; Postprandial Period; Prediabetic State; Rats; Rats, Inbred OLETF; RNA, Messenger; Sulfonylurea Compounds; Triglycerides | 2006 |
[Evaluation of first phase insulin secretion by a nateglinide-intravenous glucose insulin release test in newly diagnosed type 2 diabetics].
Topics: Adult; Case-Control Studies; Cyclohexanes; Diabetes Mellitus, Type 2; Evaluation Studies as Topic; Female; Glucose; Glucose Tolerance Test; Humans; Hypoglycemic Agents; Insulin; Insulin Secretion; Insulin-Secreting Cells; Male; Middle Aged; Nateglinide; Phenylalanine | 2006 |
Sulfonylureas and glinides exhibit peroxisome proliferator-activated receptor gamma activity: a combined virtual screening and biological assay approach.
Topics: ATP-Binding Cassette Transporters; Computer Simulation; Cyclohexanes; Diabetes Mellitus, Type 2; Drug Evaluation, Preclinical; Gene Expression Regulation; Glipizide; Humans; Hypoglycemic Agents; Nateglinide; Phenylalanine; Pioglitazone; Potassium Channels; Potassium Channels, Inwardly Rectifying; PPAR gamma; Protein Binding; Receptors, Drug; Sulfonylurea Compounds; Sulfonylurea Receptors; Thiazolidinediones | 2007 |
Safety of nateglinide as used in general practice in England: results of a prescription-event monitoring study.
Topics: Aged; Confidentiality; Cyclohexanes; Diabetes Mellitus, Type 2; Drug Monitoring; Drug Prescriptions; England; Family Practice; Female; Humans; Hypoglycemic Agents; Male; Middle Aged; Nateglinide; Phenylalanine; Safety | 2007 |
Octreotide therapy for nateglinide-induced hypoglycemia.
Topics: Aged; Blood Glucose; Cyclohexanes; Diabetes Mellitus, Type 2; Female; Gastrointestinal Agents; Glucose; Humans; Hypoglycemia; Hypoglycemic Agents; Nateglinide; Octreotide; Phenylalanine; Treatment Outcome | 2007 |
The fluorescent amino acid p-cyanophenylalanine provides an intrinsic probe of amyloid formation.
Topics: Alanine; Amino Acid Sequence; Amyloid; Benzothiazoles; Diabetes Mellitus, Type 2; Fluorescence; Fluorescent Dyes; Humans; Islet Amyloid Polypeptide; Kinetics; Molecular Sequence Data; Nitriles; Phenylalanine; Point Mutation; Protein Binding; Thiazoles; Time Factors | 2008 |
Skeletal muscle proteolysis is reduced in noninsulin-dependent diabetes mellitus and is unaltered by euglycemic hyperinsulinemia or intensive insulin therapy.
Topics: Adult; Analysis of Variance; Blood Glucose; Body Mass Index; Body Weight; Cohort Studies; Diabetes Mellitus, Type 2; Female; Glucose Clamp Technique; Glycated Hemoglobin; Humans; Infusions, Intravenous; Insulin; Kinetics; Male; Middle Aged; Muscle, Skeletal; Peptide Hydrolases; Phenylalanine; Proteins; Reference Values | 1995 |
Paradoxical structure and function in a mutant human insulin associated with diabetes mellitus.
Topics: Amino Acid Sequence; Diabetes Mellitus, Type 2; Humans; Insulin; Magnetic Resonance Spectroscopy; Models, Molecular; Molecular Sequence Data; Mutation; Phenylalanine; Protein Conformation; Protein Structure, Secondary; Receptor, Insulin; Serine; Structure-Activity Relationship | 1993 |
Glutamine and alanine metabolism in NIDDM.
Topics: Alanine; Blood Glucose; C-Peptide; Carbon Radioisotopes; Diabetes Mellitus, Type 2; Fatty Acids, Nonesterified; Female; Forearm; Glucagon; Glucose; Glutamine; Humans; Insulin; Male; Middle Aged; Phenylalanine; Radioisotope Dilution Technique; Reference Values; Tritium | 1996 |
Effects of glycerol-1,2-dimethylsuccinate and propanediol-1,2-dimethylsuccinate on insulin release and protein biosynthesis in islets of Goto-Kakizaki rats.
Topics: Animals; Diabetes Mellitus, Type 2; Glucose; Glycerides; Insulin; Islets of Langerhans; Phenylalanine; Propylene Glycols; Protein Biosynthesis; Rats; Succinates | 1997 |
Actions of the novel oral antidiabetic agent HQL-975 in genetically obese diabetic db/db mice.
Topics: 3T3 Cells; Adipocytes; Administration, Oral; Animals; Blood Glucose; Body Weight; Diabetes Mellitus, Type 2; Drinking; Eating; Glucose; Glucose Tolerance Test; Hypoglycemic Agents; Insulin; Insulin Secretion; Male; Mice; Mice, Inbred C57BL; Mice, Inbred ICR; Mice, Obese; Monosaccharide Transport Proteins; Oxazoles; Phenylalanine | 1998 |
Actions of the novel oral antidiabetic agent HQL-975 in insulin-resistant non-insulin-dependent diabetes mellitus model animals.
Topics: Administration, Oral; Animals; Deoxyglucose; Diabetes Mellitus, Type 2; Hypoglycemic Agents; Insulin Resistance; Liver; Male; Mice; Mice, Inbred Strains; Oxazoles; Phenylalanine; Rats; Rats, Inbred Strains; Rats, Wistar | 1998 |
Lipogenic action of the novel oral antidiabetic agent HQL-975 in genetically obese diabetic KK-Ay mice.
Topics: Adipose Tissue; Administration, Oral; Animals; Diabetes Mellitus, Type 2; Epididymis; Fatty Acids, Nonesterified; Glucose; Hypoglycemic Agents; Insulin; Lipids; Male; Mice; Mice, Inbred ICR; Mice, Obese; Oxazoles; Phenylalanine | 1999 |
Senaglinide. A 4166, AY 4166, Fastic, SDZ DJN 608, Starlix, Starsis, YM 026, Nateglinide.
Topics: Clinical Trials as Topic; Cyclohexanes; Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Nateglinide; Phenylalanine | 1999 |
[Fasting blood glucose has little value. Postprandial glucose indicates risk].
Topics: Blood Glucose; Cyclohexanes; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Humans; Hypoglycemic Agents; Nateglinide; Phenylalanine; Postprandial Period; Risk Factors | 2001 |
FDA approves nateglinide for treatment of type 2 diabetes.
Topics: Cyclohexanes; Diabetes Mellitus, Type 2; Drug Approval; Hypoglycemic Agents; Nateglinide; Phenylalanine; United States; United States Food and Drug Administration | 2001 |
[New glucose regulator. More comfort for the type 2 diabetic patient].
Topics: Blood Glucose; Cyclohexanes; Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Nateglinide; Phenylalanine | 2001 |
Nateglinide for type 2 diabetes.
Topics: Administration, Oral; Cyclohexanes; Diabetes Mellitus, Type 2; Dizziness; Humans; Metformin; Nateglinide; Phenylalanine | 2001 |
Early insulin release effectively improves glucose tolerance: studies in two rodent models of type 2 diabetes mellitus.
Topics: Animals; Blood Glucose; Cyclohexanes; Diabetes Mellitus, Type 2; Dietary Fats; Gastric Emptying; Glipizide; Glucose Tolerance Test; Hypoglycemic Agents; Insulin; Insulin Resistance; Insulin Secretion; Islets of Langerhans; Kinetics; Male; Nateglinide; Phenylalanine; Rats; Rats, Sprague-Dawley; Rats, Zucker | 2001 |
[Therapy of type 2 diabetes. Effective control of postprandial glucose surges].
Topics: Blood Glucose; Cyclohexanes; Diabetes Mellitus, Type 2; Drug Administration Schedule; Humans; Hypoglycemic Agents; Nateglinide; Phenylalanine; Postprandial Period | 2001 |
Immediate-Type allergy against human insulin associated with marked eosinophilia in type 2 diabetic patient.
Topics: Aged; Aged, 80 and over; Cyclohexanes; Diabetes Mellitus, Type 2; Drug Hypersensitivity; Eosinophilia; Erythema; Humans; Hypersensitivity, Immediate; Hypoglycemic Agents; Immunoglobulin E; Insulin; Male; Nateglinide; Phenylalanine; Seasons; Skin Tests | 2001 |
[Type 2 diabetes. Regulating insulin according to need].
Topics: Blood Glucose; Cyclohexanes; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Humans; Hypoglycemic Agents; Insulin; Metformin; Nateglinide; Phenylalanine; Thiazoles; Thiazolidinediones | 2001 |
Post-load hyperglycaemia-an inappropriate therapeutic target.
Topics: Blood Glucose; Cardiovascular Diseases; Cyclohexanes; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Fasting; Glucose Tolerance Test; Humans; Hypoglycemic Agents; Insulin Resistance; Metformin; Nateglinide; Patient Selection; Phenylalanine; Postprandial Period; Practice Guidelines as Topic; Predictive Value of Tests | 2002 |
Type 2 diabetes management.
Topics: Carbamates; Cyclohexanes; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Humans; Hypoglycemic Agents; Metformin; Nateglinide; Phenylalanine; Piperidines | 2002 |
Fasting and postmeal phenylalanine metabolism in mild type 2 diabetes.
Topics: Diabetes Mellitus, Type 2; Eating; Fasting; Female; Hormones; Humans; Kinetics; Male; Middle Aged; Phenylalanine | 1992 |
Aspartame metabolism in normal adults, phenylketonuric heterozygotes, and diabetic subjects.
Topics: Adult; Aspartame; Aspartic Acid; Blood Glucose; Diabetes Mellitus, Type 2; Dipeptides; Erythrocytes; Female; Glucagon; Heterozygote; Humans; Insulin; Lipids; Male; Methanol; Phenylalanine; Phenylketonurias; Reference Values | 1989 |